Compounds > metformin
Page last updated: 2024-10-30

metformin and Cancer of Lung

metformin has been researched along with Cancer of Lung in 210 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research Excerpts

ExcerptRelevanceReference
"Methods based on atomic force microscopy (AFM) were used to directly evaluate the influence of metformin on the nanomechanical and adhesive properties of endothelial and cancer cells in chronic hyperglycemia."7.96Metformin attenuates adhesion between cancer and endothelial cells in chronic hyperglycemia by recovery of the endothelial glycocalyx barrier. ( Grochot-Przeczek, A; Kloska, D; Malek-Zietek, KE; Rajfur, Z; Stepien, EŁ; Szymonski, M; Targosz-Korecka, M, 2020)
"This study aimed at investigating the effects of metformin on the growth and metastasis of esophageal squamous cell carcinoma (ESCC) in vitro and in vivo."7.88Metformin Inhibited Growth, Invasion and Metastasis of Esophageal Squamous Cell Carcinoma in Vitro and in Vivo. ( Liang, F; Wang, C; Wang, YG, 2018)
"The aim of this study was to examine the effect of metformin on the prognosis of patients with SCLC combined with diabetes mellitus (DM)."7.88Effect of metformin in the prognosis of patients with smallcell lung cancer combined with diabetes mellitus. ( Han, N; Huang, Z; Lu, H; Mao, W; Qin, J; Xie, F, 2018)
"Metformin suppressed cell growth of 9 kinds of mesothelioma including immortalized cells of mesothelium origin irrespective of the p53 functional status, whereas susceptibility to nutlin-3a was partly dependent on the p53 genotype."7.85Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways. ( Hiroshima, K; Morinaga, T; Namiki, T; Sekine, I; Shimada, H; Shimazu, K; Shingyoji, M; Tada, Y; Tagawa, M; Tatsumi, K, 2017)
"This study aimed to investigate the effect of metformin on survival of people with type 2 diabetes and pleural mesothelioma."7.83Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study. ( Brewster, DH; Damhuis, RA; Walker, J; Wild, SH; Wu, H, 2016)
"We previously found that a low dose of sorafenib had a prometastatic effect on hepatocellular carcinoma (HCC), which was caused by downregulation of TIP30 expression."7.83Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30. ( Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X, 2016)
" Importantly, metformin inhibited tumor growth and distant metastases in tumor-bearing nude mice and reversed IL-6-induced EMT both in vitro and in vivo."7.80Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. ( Cheng, X; Han, R; He, L; He, Y; Li, L; Long, H; Wang, Y; Xiang, T; Zhao, Z; Zhu, B, 2014)
" In the present study, the combined effects of metformin and gefitinib were examined in vivo in a mouse xenograft model, inoculated with a human lung adenocarcinoma cell line that possesses an activating epidermal growth factor receptor mutation."7.79Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line. ( Ashinuma, H; Chiba, T; Iwama, A; Kitamura, A; Kitazono, S; Kurosu, K; Saito-Kitazono, M; Sakaida, E; Sakao, S; Sekine, I; Tada, Y; Takiguchi, Y; Tanabe, N; Tatsumi, K; Yokosuka, O, 2013)
" We report on a case of acute kidney injury in a patient using alectinib for less than 2 weeks and on serum sodium and creatinine during long-term use of alectinib."5.72Acute kidney injury and long-term renal effects of alectinib in anaplastic lymphoma kinase-positive non-small cell lung carcinoma: a case report. ( Janssen, WMT; Roosma, E; van Londen, M; van Putten, JWG; Vogels, S, 2022)
"The metformin cells treatment reduces the migration potential in vitro and reduced the development of pulmonary metastases and the expressions of N-cadherin, vimentin, ZEB1, and ZEB2 at the metastases site, in vivo."5.72Epithelial-mesenchymal transition inhibition by metformin reduces melanoma lung metastasis in a murine model. ( Almeida, CP; da Silva, VHSR; de Araújo Campos, MR; de Carvalho, BA; de Souza Silva, FH; Del Puerto, HL; Ferreira, E; Lima, BM; Ribeiro, TS; Rocha, SA; Veloso, ES, 2022)
"Metastatic breast cancer remains a serious health concern and numerous investigations recommended medicinal plants as a complementary therapy."5.62Crocin and Metformin suppress metastatic breast cancer progression via VEGF and MMP9 downregulations: in vitro and in vivo studies. ( Abedini, MR; Arzi, L; Chamani, E; Farahi, A; Farhoudi, R; Hoshyar, R; Javdani, H; Talebloo, N, 2021)
"Abnormal glucose metabolism in cancer cells causes generation and secretion of excess lactate, which results in acidification of the extracellular microenvironment."5.62Metformin induced lactic acidosis impaired response of cancer cells towards paclitaxel and doxorubicin: Role of monocarboxylate transporter. ( Bhat, MK; Chaube, B; Deb, A; Malvi, P; Mayengbam, SS; Mohammad, N; Singh, A; Singh, SV, 2021)
" This study aimed to explore the real-world use of anti-diabetic agent metformin in combination with pemetrexed-based platinum doublets in a first-line setting."5.62Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes. ( Chang, GR; Chen, CM; Chen, W; Chong, KY; Cidem, A; Lin, CH; Staniczek, T; Tsai, YT; Wang, JL; Yen, CC, 2021)
"Metformin (MET) has recently emerged as a potentially active agent in cancer prevention and treatment."5.46Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors. ( Buzzoni, R; Concas, L; Corti, F; de Braud, F; Femia, D; Lo Russo, G; Milione, M; Perrone, F; Prinzi, N; Pulice, I; Pusceddu, S; Tamborini, E; Vernieri, C, 2017)
"Urethane is a recognized genotoxic carcinogen in fermented foods and beverages."5.43Lasting glycolytic stress governs susceptibility to urethane-induced lung carcinogenesis in vivo and in vitro. ( Cao, N; Deng, J; Du, G; Duan, Y; Geng, S; Guo, Z; Lin, H; Ma, X; Meng, M; Zheng, Y, 2016)
"Metformin administration reduced occurrence of chemotherapy induced-nausea."5.20Metformin Addition to Chemotherapy in Stage IV Non-Small Cell Lung Cancer: an Open Label Randomized Controlled Study. ( Badary, O; El Wakeel, L; Elkholy, E; Saad, AS; Sayed, R, 2015)
" We performed a systematic review and meta-analysis evaluating the effect of metformin, sulfonylureas (SUs), thiazolidinediones (TZDs), and insulin on the risk of lung cancer in patients with diabetes mellitus (DM)."4.90Anti-diabetic medications do not influence risk of lung cancer in patients with diabetes mellitus: a systematic review and meta-analysis. ( Chen, H; Lu, M; Nie, SP; Zhuang, MQ, 2014)
"Methods based on atomic force microscopy (AFM) were used to directly evaluate the influence of metformin on the nanomechanical and adhesive properties of endothelial and cancer cells in chronic hyperglycemia."3.96Metformin attenuates adhesion between cancer and endothelial cells in chronic hyperglycemia by recovery of the endothelial glycocalyx barrier. ( Grochot-Przeczek, A; Kloska, D; Malek-Zietek, KE; Rajfur, Z; Stepien, EŁ; Szymonski, M; Targosz-Korecka, M, 2020)
"This study aimed at investigating the effects of metformin on the growth and metastasis of esophageal squamous cell carcinoma (ESCC) in vitro and in vivo."3.88Metformin Inhibited Growth, Invasion and Metastasis of Esophageal Squamous Cell Carcinoma in Vitro and in Vivo. ( Liang, F; Wang, C; Wang, YG, 2018)
"The aim of this study was to examine the effect of metformin on the prognosis of patients with SCLC combined with diabetes mellitus (DM)."3.88Effect of metformin in the prognosis of patients with smallcell lung cancer combined with diabetes mellitus. ( Han, N; Huang, Z; Lu, H; Mao, W; Qin, J; Xie, F, 2018)
"Metformin suppressed cell growth of 9 kinds of mesothelioma including immortalized cells of mesothelium origin irrespective of the p53 functional status, whereas susceptibility to nutlin-3a was partly dependent on the p53 genotype."3.85Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways. ( Hiroshima, K; Morinaga, T; Namiki, T; Sekine, I; Shimada, H; Shimazu, K; Shingyoji, M; Tada, Y; Tagawa, M; Tatsumi, K, 2017)
"We previously found that a low dose of sorafenib had a prometastatic effect on hepatocellular carcinoma (HCC), which was caused by downregulation of TIP30 expression."3.83Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30. ( Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X, 2016)
"This study aimed to investigate the effect of metformin on survival of people with type 2 diabetes and pleural mesothelioma."3.83Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study. ( Brewster, DH; Damhuis, RA; Walker, J; Wild, SH; Wu, H, 2016)
" Importantly, metformin inhibited tumor growth and distant metastases in tumor-bearing nude mice and reversed IL-6-induced EMT both in vitro and in vivo."3.80Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. ( Cheng, X; Han, R; He, L; He, Y; Li, L; Long, H; Wang, Y; Xiang, T; Zhao, Z; Zhu, B, 2014)
" In the present study, the combined effects of metformin and gefitinib were examined in vivo in a mouse xenograft model, inoculated with a human lung adenocarcinoma cell line that possesses an activating epidermal growth factor receptor mutation."3.79Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line. ( Ashinuma, H; Chiba, T; Iwama, A; Kitamura, A; Kitazono, S; Kurosu, K; Saito-Kitazono, M; Sakaida, E; Sakao, S; Sekine, I; Tada, Y; Takiguchi, Y; Tanabe, N; Tatsumi, K; Yokosuka, O, 2013)
" We found that in LKB1-null A549 lung adenocarcinoma cells, an AMPK activator, metformin, failed to block the nuclear export of PTEN, and the reintroduction of functional LKB1 into these cells restored the metformin-mediated inhibition of the nuclear export of PTEN."3.77AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor. ( Gallick, GE; Liu, JL; Mao, Z; Yung, WK, 2011)
"Metformin, the first-line drug for treating diabetes, selectively kills the chemotherapy resistant subpopulation of cancer stem cells (CSC) in genetically distinct types of breast cancer cell lines."3.77Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. ( Hirsch, HA; Iliopoulos, D; Struhl, K, 2011)
"Lung, prostate, and breast cancer cells were treated with IR (2-8 Gy) after incubation with either ATM or AMPK inhibitors or the AMPK activator metformin."3.76Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. ( Bristow, RG; Cutz, JC; Harding, S; Liu, C; Rashid, A; Sanli, T; Singh, G; Tsakiridis, T; Wright, J, 2010)
"In this patient, lactic acidosis was promoted by erlotinib-related hepatitis with initial liver failure (decreased lactate clearance), concomitant metformin treatment (increased lactate production), and acute renal deterioration (metformin accumulation)."3.75Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer. ( Fimognari, FL; Franco, A; Pastorelli, R; Pellegrinotti, M; Repetto, L, 2009)
"We investigated the effects of metformin on the growth of lewis lung LLC1 carcinoma in C57BL/6J mice provided with either a control diet or a high-energy diet, previously reported to lead to weight gain and systemic insulin resistance with hyperinsulinemia."3.74Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. ( Algire, C; Blouin, MJ; Pollak, M; Shuai, JH; Zakikhani, M, 2008)
"Metformin has anticancer properties, and studies suggest synergism between metformin and pemetrexed."3.30A phase II study of metformin plus pemetrexed and carboplatin in patients with non-squamous non-small cell lung cancer (METALUNG). ( Chitikela, S; Gupta, Y; Jain, D; Khurana, S; Kumar, S; Malik, PS; Pushpam, D; Singh, V; Verma, S, 2023)
" Here, we investigate the pharmacokinetic drug-drug interaction potential of trilaciclib."3.11Pharmacokinetic Drug-Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer. ( Beelen, A; Curd, L; Goti, V; Horton, JK; Li, C; Sale, M; Tao, W, 2022)
"Metformin has significant data supporting its use as an antineoplastic agent."3.01Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non-Small Cell Lung Cancer: The NRG-LU001 Phase 2 Randomized Clinical Trial. ( Bazan, J; Bradley, JD; Coster, J; Doemer, AJ; Erasmus, JJ; Esparaz, BT; Hu, C; Lee, RY; Lu, B; McCormack, SE; McGarry, RC; Paulus, R; Santana-Davila, R; Schaner, PE; Skinner, H; Struve, T; Tsakiridis, T; Videtic, GMM; Werner-Wasik, M; Yang, AX, 2021)
"Metformin is a biguanide, widely used as a first‑line oral drug in treating type 2 diabetes."3.01Research progress on the therapeutic effect and mechanism of metformin for lung cancer (Review). ( Han, P; Liu, Q; Sun, K; Xiang, J; Zhou, J, 2023)
"Metformin has been shown to have antitumor effects via a variety of insulin-dependent and insulin-independent mechanisms and to be potentially synergistic with chemotherapy."2.87A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer. ( Brahmer, JR; Coleman, B; Ettinger, DS; Forde, PM; Gabrielson, E; Hann, CL; Kelly, RJ; Marrone, KA; Purtell, M; Rosner, GL; Zhou, X, 2018)
" The recommended dose of metformin combined with nivolumab is determined in part 1."2.87Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors. ( Fujiwara, T; Hotta, K; Kiura, K; Kozuki, T; Kubo, T; Ninomiya, T; Okada, H; Toyooka, S; Udono, H, 2018)
"Metformin was initiated at 1000 mg/day for week 1, 1500 mg/day for week 2, then 2000 mg/day thereafter, in divided doses."2.84Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial. ( Becker, DJ; Kozuch, P; Levy, BP; Parikh, AB; Rohs, N, 2017)
"Lung cancer is a disease that seriously endangers human health, its morbidity and mortality have been ranked first among all malignant tumors, and the prognosis is poor."2.66[Research Advance in Anti-lung Cancer Mechanism of Metformin]. ( Wang, G; Xie, M; Xu, M, 2020)
"Metformin treatment was associated with decreased lung cancer incidence (HR 0."2.66The effect of metformin on lung cancer risk and survival in patients with type 2 diabetes mellitus: A meta-analysis. ( Li, X; Liu, F; Liu, J; Wu, Q; Xiao, K; Xu, J, 2020)
"Metformin use was related to a lower lung cancer risk in diabetic patients compared to nonusers, but this result was retrieved from observational studies and our findings need more well-designed RCTs to confirm the association."2.61Metformin Use and Lung Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis. ( He, W; Huang, X; Huang, Y; Liu, M; Wu, K; Yao, L; Zhang, R; Zhao, Y, 2019)
"Clinical trials in pre-surgical endometrial cancer patients exhibited a significant decrease in Ki67 with metformin monotherapy."2.53Repurposing metformin for cancer treatment: current clinical studies. ( Altman, JK; Arya, A; Carneiro, B; Chae, YK; Chandra, S; Giles, F; Kalyan, A; Kaplan, J; Malecek, MK; Platanias, L; Shin, DS, 2016)
"Metformin therapy was associated with significantly lower risks of cancers of the lung (4 studies; pooled relative risk = 0."2.50Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis. ( Bi, Y; Guo, Y; Li, S; Song, Q; Zhang, Q; Zhang, ZJ; Zhao, G, 2014)
"Metformin is a widely used antidiabetic drug, which also displays significant growth inhibitory and proapoptotic effects in several cancer models, including lung cancer, alone or in combination with chemotherapeutic drugs."2.49Metformin in lung cancer: rationale for a combination therapy. ( Capuano, A; Ciardiello, F; Della Corte, CM; Festino, L; Manzo, A; Martinelli, E; Morgillo, F; Sasso, FC; Troiani, T, 2013)
"Metformin dose was significantly correlated with drug concentrations in all tissues analysed."1.91Tumour, whole-blood, plasma and tissue concentrations of metformin in lung cancer patients. ( Demidenko, E; Fay, K; Hampsch, RA; Lewis, LD; Miller, TW; Ness, DB; Phillips, JD; Pooler, DB; Tau, S, 2023)
"No evidence exists as to whether type 2 diabetes mellitus (T2DM) impairs clinical outcome from immune checkpoint inhibitors (ICI) in patients with solid tumors."1.91Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer. ( Ascierto, PA; Bersanelli, M; Bordi, P; Botticelli, A; Bracarda, S; Brunetti, L; Buti, S; Cannita, K; Chiari, R; Cleary, S; Cortellini, A; D'Alessio, A; De Tursi, M; Di Marino, P; Falconi, M; Ferrari, M; Ficorella, C; Filetti, M; Gelibter, A; Gennari, A; Ghidini, M; Giorgi, FC; Giusti, R; Grossi, F; Inno, A; Lo Bianco, F; Macrini, S; Mallardo, D; Marchetti, P; Marconcini, R; Morganstein, DL; Nibid, L; Nicolardi, L; Nigro, O; Pantano, F; Pergolesi, F; Perrone, G; Pinato, DJ; Queirolo, P; Rastelli, F; Russano, M; Russo, A; Sabarese, G; Santini, D; Sergi, MC; Siringo, M; Spagnolo, F; Spoto, C; Stucci, LS; Tanda, ET; Tonini, G; Tucci, M; Veltri, E; Vincenzi, B; Vitale, MG; Zarzana, MA; Zoratto, F, 2023)
"Modulation of AMPK may have a role in cervical cancer treatment."1.91Radiosensitising Effects of Metformin Added to Concomitant Chemoradiotherapy with Cisplatin in Cervical Cancer. ( Beduk Esen, CS; Canpinar, H; Gedik, ME; Gultekin, M; Gunaydin, G; Yedekci, FY; Yildiz, F, 2023)
"Metformin can inhibit the growth of many cancer cells through various mechanisms, including ferroptosis."1.91Metformin induces ferroptosis through the Nrf2/HO-1 signaling in lung cancer. ( Chen, Y; Deng, C; Wu, J; Wu, K; Xiong, L, 2023)
"Sotorasib is an oral, small molecule inhibitor of the Kirsten rat sarcoma oncogene homolog (KRAS) G12C mutant protein (KRASG12C) protein approved by the U."1.91Impact of Sotorasib on the Pharmacokinetics and Pharmacodynamics of Metformin, a MATE1/2K Substrate, in Healthy Subjects. ( Houk, BE; Vuu, I; Wahlstrom, J, 2023)
"Metformin use was measured according to metformin prescriptions dispensed to patients in the VA health system."1.72Identification of patient characteristics associated with survival benefit from metformin treatment in patients with stage I non-small cell lung cancer. ( Barbi, J; Elkin, PL; McCray, W; Mullin, S; Resendez, SD; Tetewsky, S; Yendamuri, S, 2022)
"Metformin is a widely used drug for type 2 diabetes mellitus and has recently attracted broad attention for its therapeutic effects on many cancers."1.72Knockdown of NUPR1 Enhances the Sensitivity of Non-small-cell Lung Cancer Cells to Metformin by AKT Inhibition. ( Hong, SE; Jang, SK; Jin, HO; Kim, CH; Kim, YJ; Park, IC; Park, KS, 2022)
" We report on a case of acute kidney injury in a patient using alectinib for less than 2 weeks and on serum sodium and creatinine during long-term use of alectinib."1.72Acute kidney injury and long-term renal effects of alectinib in anaplastic lymphoma kinase-positive non-small cell lung carcinoma: a case report. ( Janssen, WMT; Roosma, E; van Londen, M; van Putten, JWG; Vogels, S, 2022)
"The metformin cells treatment reduces the migration potential in vitro and reduced the development of pulmonary metastases and the expressions of N-cadherin, vimentin, ZEB1, and ZEB2 at the metastases site, in vivo."1.72Epithelial-mesenchymal transition inhibition by metformin reduces melanoma lung metastasis in a murine model. ( Almeida, CP; da Silva, VHSR; de Araújo Campos, MR; de Carvalho, BA; de Souza Silva, FH; Del Puerto, HL; Ferreira, E; Lima, BM; Ribeiro, TS; Rocha, SA; Veloso, ES, 2022)
"Metformin has displayed the intense anti-inflammation and anti-cancer properties through regulating pyroptosis."1.72Metformin antagonizes nickel-refining fumes-induced cell pyroptosis via Nrf2/GOLPH3 pathway in vitro and in vivo. ( Chen, Y; Gao, Y; Jin, S; Li, L; Wang, Y; Wu, Y; Yang, S; Yao, W; Zhang, D; Zhang, T, 2022)
"Metformin has been found to have inhibitory effects on a variety of tumors."1.72Metformin inhibits human non-small cell lung cancer by regulating AMPK-CEBPB-PDL1 signaling pathway. ( Bi, G; Chen, Z; Huang, Y; Jiang, W; Li, M; Liang, J; Lin, Z; Lu, T; Tan, L; Wang, Q; Xi, J; Zhan, C; Zhao, M; Zheng, Y, 2022)
"001) in a dose-response fashion, and these associations were prominent among participants with a metformin cumulative defined daily dose of 547."1.62The Associations of Aspirin, Statins, and Metformin With Lung Cancer Risk and Related Mortality: A Time-Dependent Analysis of Population-Based Nationally Representative Data. ( Cho, JH; Cho, M; Jeong, SM; Kang, J; Kim, J; Shin, DW, 2021)
"Metformin use was associated with improved survival, especially LCSS in patients with regional stage SCC."1.62Metformin use and lung cancer survival: a population-based study in Norway. ( Botteri, E; Brancher, S; Damhuis, RAM; Johannesen, TB; Strand, TE; Støer, NC; Weiderpass, E, 2021)
"Metformin is an antidiabetic drug that has been reported to have antitumor activity in many cancer types."1.62Inhibition of AKT Enhances the Sensitivity of NSCLC Cells to Metformin. ( Hong, J; Hong, SE; Jang, SK; Jin, HO; Kim, JY; Lee, DH; Park, IC, 2021)
" This study aimed to explore the real-world use of anti-diabetic agent metformin in combination with pemetrexed-based platinum doublets in a first-line setting."1.62Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes. ( Chang, GR; Chen, CM; Chen, W; Chong, KY; Cidem, A; Lin, CH; Staniczek, T; Tsai, YT; Wang, JL; Yen, CC, 2021)
"Metastatic breast cancer remains a serious health concern and numerous investigations recommended medicinal plants as a complementary therapy."1.62Crocin and Metformin suppress metastatic breast cancer progression via VEGF and MMP9 downregulations: in vitro and in vivo studies. ( Abedini, MR; Arzi, L; Chamani, E; Farahi, A; Farhoudi, R; Hoshyar, R; Javdani, H; Talebloo, N, 2021)
"Abnormal glucose metabolism in cancer cells causes generation and secretion of excess lactate, which results in acidification of the extracellular microenvironment."1.62Metformin induced lactic acidosis impaired response of cancer cells towards paclitaxel and doxorubicin: Role of monocarboxylate transporter. ( Bhat, MK; Chaube, B; Deb, A; Malvi, P; Mayengbam, SS; Mohammad, N; Singh, A; Singh, SV, 2021)
"Metformin has been widely used as the treatment of type II diabetes mellitus for its anti-hyperglycemic effect."1.62Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC). ( Chae, YK; Cho, S; Choi, H; Choi, J; Gim, G; Kang, CY; Kim, L; Kim, Y; Lee, JY; Park, I; Vagia, E; Viveiros, P, 2021)
" Metformin use also exhibited significant dose-response relationship with respect to the risks of bacterial pneumonia, hospitalization for COPD and IMV."1.56Respiratory outcomes of metformin use in patients with type 2 diabetes and chronic obstructive pulmonary disease. ( Hsu, CC; Hwu, CM; Wei, JC; Yang, YC; Yen, FS, 2020)
"Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has sufficient clinical efficacy and satisfactory safety in ALK-positive non-small cell lung cancer (NSCLC) patients with or without brain metastasis."1.56Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1. ( Chen, H; Feng, M; Han, R; He, Y; Hu, C; Li, L; Lin, C; Lu, C; Peng, T; Sun, F; Wang, Y, 2020)
"Metformin has an inhibitory effect on lung cancer and regulates the expression of certain microRNAs, but there is no report connecting metformin with microRNA-7 in lung cancer."1.56Metformin mediated microRNA-7 upregulation inhibits growth, migration, and invasion of non-small cell lung cancer A549 cells. ( Chen, D; Chen, L; Dong, J; Liu, J; Peng, H; Wu, W; Yang, X; Zhao, Y, 2020)
" We conducted a retrospective cohort study using data from the claims database of Taipei Veterans General Hospital to perform direct comparisons of these three EGFR-TKIs (gefitinib, erlotinib, and afatinib) combined with co-medications (metformin, statins, antacids, and steroids)."1.56The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer. ( Chang, YL; Chen, YM; Chou, YC; He, CH; Hsu, CC; Huang, TY; Su, VY; Yang, KY; Yen, JC, 2020)
"Metformin treatment also significantly reduced tumor formation in vivo as well as protein expression of PCNA, Akt, Myc, and serine phosphorylation of the latter 2, which can be partially blocked by O/E α4 or sh-PP2Ac."1.51Metformin Inhibit Lung Cancer Cell Growth and Invasion in Vitro as Well as Tumor Formation in Vivo Partially by Activating PP2A. ( Jiang, W; Lin, X; Liu, J; Liu, S; Mao, X; Xu, L; Zhang, Z; Zhou, H; Zhou, X, 2019)
" Many researchers have reported immune-mediated adverse events induced by immune checkpoint inhibitors (ICI) single agent."1.51Inflammatory bowel disease associated with the combination treatment of nivolumab and metformin: data from the FDA adverse event reporting system. ( Liu, J; Zhang, L; Zhang, Y; Zhou, H, 2019)
"Metformin is a drug commonly used in the treatment of diabetes and with anticancer activity."1.48The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC. ( Gao, Y; Guo, J; Jin, D; Shao, C; Tan, S; Wang, D; Wang, X; Wu, Y; Xu, X, 2018)
"Recurrences, metastases, secondary cancers, survival and carcinoembryonic antigen levels were compared using t test and chi-squared test."1.46Metformin Has Positive Therapeutic Effects in Colon Cancer and Lung Cancer. ( Frieson, D; Henderson, D; Solomon, SS; Zuber, J, 2017)
"Metformin (MET) has recently emerged as a potentially active agent in cancer prevention and treatment."1.46Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors. ( Buzzoni, R; Concas, L; Corti, F; de Braud, F; Femia, D; Lo Russo, G; Milione, M; Perrone, F; Prinzi, N; Pulice, I; Pusceddu, S; Tamborini, E; Vernieri, C, 2017)
"Treatment with metformin alone and in combination with pioglitazone resulted in statistically significant decreases in lung adenoma formation at both early- and late-stage interventions."1.46Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention. ( Antonides, JD; Clapper, ML; Galbraith, AR; Haynes, AM; Miller, KA; Miller, MS; Miller, WA; O'Sullivan, MG; Ondrey, FG; Seabloom, DE; Steele, VE; Wuertz, BR, 2017)
"Urethane is a recognized genotoxic carcinogen in fermented foods and beverages."1.43Lasting glycolytic stress governs susceptibility to urethane-induced lung carcinogenesis in vivo and in vitro. ( Cao, N; Deng, J; Du, G; Duan, Y; Geng, S; Guo, Z; Lin, H; Ma, X; Meng, M; Zheng, Y, 2016)
"Pretreatment of metformindownregulation of c-FLIP and markedly enhanced TRAIL-induced tumor cell death by dose-dependent manner."1.43Activation of autophagy flux by metformin downregulates cellular FLICE-like inhibitory protein and enhances TRAIL- induced apoptosis. ( Eo, SK; Lee, JH; Lee, YJ; Moon, JH; Nazim, UM; Park, SY; Seol, JW, 2016)
"Metformin use was independently associated with a better OS."1.43Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer. ( Arrieta, O; Cardona, AF; De la Torre-Vallejo, M; Muñiz-Hernández, S; Sánchez-Reyes, R; Soto-Perez-de-Celis, E; Varela-Santoyo, E, 2016)
"GSKJ4, alone and in combination with an anti-diabetic drug metformin, induced cell death and inhibited the growth of NSCLC cell lines efficiently at concentrations non-toxic to normal cells, irrespective of their genetic backgrounds (mutations in the KRAS, TP53 and EGFR genes) and also of their resistance to cisplatin and paclitaxel."1.43Impact of H3K27 Demethylase Inhibitor GSKJ4 on NSCLC Cells Alone and in Combination with Metformin. ( Kitanaka, C; Kuramoto, K; Oizumi, H; Okada, M; Sadahiro, M; Sakaki, H; Seino, S; Suzuki, S; Takeda, H; Watarai, H, 2016)
" This study aimed to evaluate the effect of metformin in combination with EGFR-TKI on the prognosis of non-small cell lung cancer (NSCLC) patients with diabetes mellitus type 2 (DM2)."1.42Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes. ( Cao, M; Chen, H; Chu, Q; Han, R; He, Y; Sun, J; Wang, D; Wang, Y; Yao, W, 2015)
"Recurrent type I endometrial cancer (EC) has poor prognosis and demands novel therapeutic approaches."1.42Metformin: a modulator of bevacizumab activity in cancer? A case report. ( Aliberti, C; Casarin, A; Indraccolo, S; Nardin, M; Nicoletto, MO; Pomerri, F; Randon, G; Zulato, E, 2015)
"The metformin was used in 120 (46."1.42Metformin use improves the survival of diabetic combined small-cell lung cancer patients. ( Chen, L; Gao, F; Jia, Y; Kong, F; Li, X; Liu, G; Liu, H; Yu, J; Zheng, R, 2015)
" Some observational studies have shown a reduced risk of lung cancer in DM patients taking metformin, but a dose-response relationship has never been reported."1.40Metformin decreases lung cancer risk in diabetic patients in a dose-dependent manner. ( Chang, PY; Chiu, HC; Huang, MS; Kung, YT; Shen, YT; Sheu, CC; Tsai, MJ; Yang, CJ, 2014)
"Metformin treatment reduced expression of miR-222 in these cells (p < 0."1.39Metformin inhibits lung cancer cells proliferation through repressing microRNA-222. ( Chu, X; Dai, W; Sun, Y; Wang, Y; Yang, B; Zhao, M, 2013)
"Metformin was concluded to function as a potential K-ras-targeting agent that has potential for cancer therapy."1.39K‑ras gene mutation as a predictor of cancer cell responsiveness to metformin. ( Guo, FC; Li, D; Ma, Y; Shi, HS; Wang, W; Wang, YS, 2013)
"Treatment with metformin as single agent, however, induced an activation and phosphorylation of mitogen-activated protein kinase (MAPK) through an increased C-RAF/B-RAF heterodimerization."1.39Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. ( Ciardiello, F; D'Aiuto, E; De Palma, R; De Vita, F; Della Corte, CM; Martinelli, E; Morgillo, F; Orditura, M; Sasso, FC; Troiani, T; Vitagliano, D, 2013)
"Metformin has been used as first-line treatment in patients with type 2 diabetes, and is reported to reduce cancer risk and progression by activating the liver kinase B1 (LKB1)-AMP-activated protein kinase (AMPK) pathway."1.39Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway. ( Chen, HH; Huang, WL; Lai, WW; Lin, CC; Su, WC; Su, WP; Yan, JJ; Yeh, HH, 2013)
"Metformin use was not associated with a decreased rate of lung cancer (rate ratio 0."1.39The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. ( Azoulay, L; Pollak, MN; Smiechowski, BB; Suissa, S; Yin, H, 2013)
"Metformin use has been linked to a decreased cancer risk."1.38Metformin does not alter the risk of lung cancer: a case-control analysis. ( Becker, C; Bodmer, M; Jick, SS; Meier, CR, 2012)
"A2780 ovarian cancer cells were injected intraperitoneally in nude mice; A2780-induced tumors in nude mice, when treated with metformin in drinking water, resulted in a significant reduction of tumor growth, accompanied by inhibition of tumor cell proliferation (as assessed by immunohistochemical staining of Ki-67, Cyclin D1) as well as decreased live tumor size and mitotic cell count."1.37Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. ( Giri, S; Graham, RP; Maguire, JL; Rattan, R; Shridhar, V, 2011)
"Identifying novel drugs for treatment of lung cancer remains of utmost importance, and, in recent years, targeted therapies have been acknowledged as particularly attractive."1.36Teaching an old drug new tricks: metformin as a targeted therapy for lung cancer. ( Antonoff, MB; D'Cunha, J, 2010)

Research

Studies (210)

TimeframeStudies, this research(%)All Research%
pre-19901 (0.48)18.7374
1990's0 (0.00)18.2507
2000's3 (1.43)29.6817
2010's125 (59.52)24.3611
2020's81 (38.57)2.80

Authors

AuthorsStudies
Heishima, K1
Sugito, N1
Soga, T1
Nishikawa, M1
Ito, Y1
Honda, R1
Kuranaga, Y1
Sakai, H1
Ito, R1
Nakagawa, T1
Ueda, H1
Akao, Y1
Lu, T1
Li, M2
Zhao, M2
Huang, Y5
Bi, G1
Liang, J2
Chen, Z2
Zheng, Y3
Xi, J2
Lin, Z2
Zhan, C1
Jiang, W2
Wang, Q4
Tan, L1
Arrieta, O5
Zatarain-Barrón, ZL2
Turcott, JG1
Barrón, F1
Yendamuri, S2
Cardona, AF2
Rosell, R1
Chen, N1
Zhou, YS1
Wang, LC1
Huang, JB1
Atasoy, O1
Cini, N1
Erdogan, MA1
Yaprak, G1
Erbas, O1
Salmani Javan, E1
Lotfi, F1
Jafari-Gharabaghlou, D1
Mousazadeh, H1
Dadashpour, M1
Zarghami, N1
Sun, X3
Dong, M1
Gao, Y5
Wang, Y16
Du, L2
Liu, Y9
Ji, K2
He, N1
Wang, J6
Zhang, M5
Gu, Y1
Song, H3
Zhai, H1
Feng, L1
Xu, C3
Liu, Q5
Elkin, PL1
Mullin, S1
Tetewsky, S1
Resendez, SD1
McCray, W1
Barbi, J1
Tojo, M1
Miyato, H1
Koinuma, K1
Horie, H1
Tsukui, H1
Kimura, Y1
Kaneko, Y1
Ohzawa, H1
Yamaguchi, H1
Yoshimura, K1
Lefor, AK1
Sata, N1
Kitayama, J1
Qiu, C1
Li, C4
Zheng, Q1
Fang, S1
Xu, J4
Wang, H5
Guo, H1
Jafarzadeh, E1
Montazeri, V1
Aliebrahimi, S1
Sezavar, AH1
Ghahremani, MH1
Ostad, SN1
Schlesser, C1
Meul, T1
Stathopoulos, G1
Meiners, S1
Kim, YJ2
Hong, SE2
Jang, SK2
Park, KS1
Kim, CH1
Park, IC2
Jin, HO2
Horton, JK1
Sale, M1
Curd, L1
Goti, V1
Tao, W1
Beelen, A1
Phillips, JD1
Pooler, DB1
Ness, DB1
Fay, K1
Tau, S1
Demidenko, E1
Hampsch, RA1
Lewis, LD1
Miller, TW1
van Londen, M1
Roosma, E1
Vogels, S1
van Putten, JWG1
Janssen, WMT1
Veloso, ES1
de Carvalho, BA1
de Souza Silva, FH1
Ribeiro, TS1
Lima, BM1
Almeida, CP1
da Silva, VHSR1
Rocha, SA1
de Araújo Campos, MR1
Del Puerto, HL1
Ferreira, E1
Zhang, T5
Yao, W2
Chen, Y6
Zhang, D3
Jin, S1
Li, L13
Yang, S2
Wu, Y5
Yang, J1
Kim, SH1
Jung, EH1
Kim, SA1
Suh, KJ1
Lee, JY2
Kim, JW2
Lee, JO1
Lee, KW1
Kim, JH1
Bang, SM1
Lee, JS2
Han, P1
Zhou, J1
Xiang, J1
Sun, K1
Chen, HF3
Lin, R3
Hsu, CX3
Vuu, I1
Wahlstrom, J1
Houk, BE1
Zhang, F4
Liu, W1
Long, Y1
Peng, H2
Elton, AC1
Cedarstrom, V1
Quraishi, A1
Wuertz, B1
Murray, K1
Markowski, TW1
Seabloom, D1
Ondrey, FG2
Dong, Y2
Hu, H2
Zhang, X6
Zhang, Y9
Kan, W1
Tan, MJ1
Shi, H1
Zang, Y1
Li, J8
Barrios-Bernal, P2
Lucio-Lozada, J1
Ramos-Ramírez, M1
Hernández-Pedro, N2
Lee, BB2
Kim, D2
Kim, Y6
Han, J3
Shim, YM2
Kim, DH2
Cortellini, A1
D'Alessio, A1
Cleary, S1
Buti, S1
Bersanelli, M1
Bordi, P1
Tonini, G1
Vincenzi, B1
Tucci, M1
Russo, A1
Pantano, F1
Russano, M1
Stucci, LS1
Sergi, MC1
Falconi, M1
Zarzana, MA1
Santini, D1
Spagnolo, F1
Tanda, ET1
Rastelli, F1
Giorgi, FC1
Pergolesi, F1
Giusti, R1
Filetti, M1
Lo Bianco, F1
Marchetti, P1
Botticelli, A1
Gelibter, A1
Siringo, M1
Ferrari, M1
Marconcini, R1
Vitale, MG2
Nicolardi, L1
Chiari, R1
Ghidini, M1
Nigro, O1
Grossi, F1
De Tursi, M1
Di Marino, P1
Queirolo, P1
Bracarda, S1
Macrini, S1
Inno, A1
Zoratto, F1
Veltri, E1
Spoto, C1
Cannita, K1
Gennari, A1
Morganstein, DL1
Mallardo, D1
Nibid, L1
Sabarese, G1
Brunetti, L1
Perrone, G1
Ascierto, PA1
Ficorella, C1
Pinato, DJ1
Seo, DS1
Joo, S1
Baek, S1
Kang, J4
Kwon, TK1
Jang, Y1
Verma, S1
Chitikela, S1
Singh, V1
Khurana, S1
Pushpam, D1
Jain, D1
Kumar, S1
Gupta, Y1
Malik, PS1
Lara-Mejía, L1
Yadav, P1
Makwana, S1
Bansal, S1
Soni, S1
Mahapatra, MK1
Bandyopadhayaya, S1
Tailor, R1
Shrivastava, SK1
Sharma, LK1
Mandal, CC1
Beduk Esen, CS1
Gedik, ME1
Canpinar, H1
Yedekci, FY1
Yildiz, F1
Gunaydin, G1
Gultekin, M1
Deng, C1
Xiong, L1
Wu, K3
Wu, J6
Chen, M1
Li, Y7
Jia, B1
Liu, X3
Ma, T1
Jiang, L1
Zhao, Y8
Zhang, XJ1
Wu, G3
Zhou, X5
Sun, J3
Bai, J1
Ren, B1
Tian, K1
Xu, Z2
Xiao, HL1
Zhou, Q1
Han, R7
Chen, H7
Yang, Z2
Gao, C3
Cai, S3
He, Y12
Stirrups, R1
Dong, S1
Ruiz-Calderon, B1
Rathinam, R1
Eastlack, S1
Maziveyi, M1
Alahari, SK1
Lin, C4
Lu, C4
Hao, S1
Zhou, H4
Shen, J4
Fang, W1
Liu, J5
Zhang, L5
Dong, J1
Yang, X4
Wu, W3
Chen, D2
Chen, L6
Jin, D2
Guo, J3
Chen, W4
Du, J3
Yang, L3
Wang, X10
Gong, K1
Dai, J1
Miao, S1
Li, X14
Su, G1
Targosz-Korecka, M1
Malek-Zietek, KE1
Kloska, D1
Rajfur, Z1
Stepien, EŁ1
Grochot-Przeczek, A1
Szymonski, M1
Kang, YT1
Hsu, WC1
Ou, CC1
Tai, HC1
Hsu, HT1
Yeh, KT1
Ko, JL1
Chun, SG1
Liao, Z1
Jeter, MD1
Chang, JY1
Lin, SH1
Komaki, RU1
Guerrero, TM1
Mayo, RC1
Korah, BM1
Koshy, SM1
Heymach, JV1
Koong, AC1
Skinner, HD1
Peng, T3
Hu, C2
Feng, M1
Sun, F2
Hue-Fontaine, L1
Lemelin, A1
Forestier, J1
Raverot, G1
Milot, L1
Robinson, P1
Borson-Chazot, F1
Lombard-Bohas, C1
Walter, T1
Danila, E1
Linkevičiūtė-Ulinskienė, D1
Zablockis, R1
Gruslys, V1
Cicėnas, S1
Smailytė, G1
Ramirez-Tirado, LA1
Svaton, M1
Zemanova, M1
Zemanova, P1
Kultan, J1
Fischer, O1
Skrickova, J1
Jakubikova, L1
Cernovska, M1
Hrnciarik, M1
Jirousek, M1
Krejci, J1
Krejci, D1
Bilek, O1
Blazek, J1
Hurdalkova, K1
Barinova, M1
Melichar, B1
Wang, G1
Xu, M2
Xie, M1
Yarmolinsky, J1
Bull, CJ1
Walker, VM1
Nounu, A1
Davey Smith, G1
Williams, DM1
Georgakis, MK1
Xiao, K1
Liu, F1
Wu, Q2
Shen, X1
Liu, G2
Zhou, HL1
Fan, J1
Li, YL1
Xu, ZX1
Kim, J2
Hyun, HJ1
Choi, EA1
Yoo, JW1
Lee, S1
Jeong, N2
Shen, JJ1
You, HS1
Kim, YS1
Kang, HT1
Yen, FS1
Wei, JC1
Yang, YC1
Hsu, CC2
Hwu, CM1
Mormile, R2
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Li, H5
Yu, D2
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S3
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Zhang, S3
Xing, YL1
Chen, MA1
Sun, Y3
Neradilek, MB1
Wu, XT1
Huang, W1
Cui, Y2
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xiang, Y1
Xu, X2
Zhou, L2
Dong, X1
Tang, S1
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
Tong, F1
Dong, JH1
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Shan, A1
Zhao, H2
Wu, M2
Ma, Q1
Zhang, E1
Zhang, J4
Xue, F1
Deng, L2
Liu, L3
Yan, Z2
Meng, J1
Chen, G3
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Ren, Y1
Li, P1
Jiao, Q1
Meng, P1
Wang, F2
Wang, YS3
Wang, C5
Wang, W2
Wang, S2
Hou, J1
Zhang, A1
Lv, B1
Pang, D1
Lu, K1
Ahmad, NH1
Wang, L1
Zhu, J2
Zhuang, T1
Tu, J1
Zhao, Z2
Qu, Y1
Yao, H1
Lee, DF1
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Wu, X1
Lu, J2
Li, W2
Du, F1
Ji, H1
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z2
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y2
Na, KJ1
Choi, H2
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S2
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J1
Kong, X1
Li, S2
Zhang, H1
Yang, T3
Xu, Y1
Yuan, Z1
Cao, J2
Luo, Z1
Mei, Z1
Yao, Y1
Liu, Z2
Liang, C1
Yang, H3
Song, Y2
Yu, K1
Zhu, C1
Huang, Z2
Qian, J1
Ge, J2
Hu, J2
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Rathore, MG1
Reddy, K1
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W1
Liu, C4
Gao, F3
Qi, Y1
Lu, H3
Cai, X2
Ji, RY1
Hou, Y4
Tian, J3
Shi, Y1
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Wu, D3
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Qi, J2
Mu, J1
Cong, Z1
Chen, S3
Fu, D1
Li, Z2
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Lu, Y1
Hu, X1
Wei, H1
Wang, Z2
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Zhang, Q4
Lyu, Y1
Huang, J1
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A1
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A2
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Li, D4
Tan, H1
Maji, TK1
J R, A1
Mukherjee, S1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y3
Gao, W1
Ma, S1
Lin, W1
Zhou, T1
Wu, T1
Ye, C1
He, X1
Jiang, F1
Yuan, D1
Chen, Q1
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J2
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Yang, Y1
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Zhang, YY1
Zhu, Y1
Lu, DZ1
Dong, W3
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H2
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H4
He, Z1
Chen, B1
Du, X1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Chen, X1
Duong, F1
Kong, W1
Chang, JH1
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Jiang, Y1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Chen, J2
Shao, Z1
Yuan, C1
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B2
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Feng, X2
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Meng, Y1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T1
Li, Q3
Cao, T1
Guo, L1
Fu, Y2
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J1
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ2
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P2
Nabi, M1
Cai, Y1
Li, F1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Su, VY1
Yang, KY1
Huang, TY1
Chen, YM1
Yen, JC1
Chou, YC1
Chang, YL1
He, CH1
Yu, S1
Lan, Y1
Ma, X2
Zhu, R1
Jeong, SM1
Shin, DW1
Cho, M1
Cho, JH1
Vagia, E1
Viveiros, P1
Kang, CY1
Gim, G1
Cho, S1
Kim, L1
Park, I1
Choi, J1
Chae, YK2
Fatehi Hassanabad, A1
MacQueen, KT1
Singh, SV1
Chaube, B1
Mayengbam, SS1
Malvi, P1
Mohammad, N1
Deb, A1
Bhat, MK1
Bland, AR1
Shrestha, N1
Bower, RL1
Rosengren, RJ1
Ashton, JC1
Brancher, S2
Støer, NC1
Weiderpass, E2
Damhuis, RAM1
Johannesen, TB1
Botteri, E1
Strand, TE1
Lee, Y1
Joo, J1
Lee, YJ2
Lee, EK1
Kim, TS1
Lee, SH1
Kim, SY1
Wie, GA1
Park, M1
Han, JY1
Shojaee, S1
Nana-Sinkam, P1
Wang, M1
Tong, Y1
Marciano, O1
Mehazri, L1
Shpungin, S1
Varvak, A1
Zacksenhaus, E1
Nir, U1
Fan, H1
Bai, S1
Guan, X1
Ma, W1
Morelli, AP1
Tortelli, TC1
Pavan, ICB1
Silva, FR1
Granato, DC1
Peruca, GF1
Pauletti, BA1
Domingues, RR1
Bezerra, RMN1
De Moura, LP1
Paes Leme, AF1
Chammas, R1
Simabuco, FM1
Farahi, A1
Abedini, MR1
Javdani, H1
Arzi, L1
Chamani, E1
Farhoudi, R1
Talebloo, N1
Hoshyar, R1
Qiu, Y1
Cheng, L1
Lee, DH1
Kim, JY2
Hong, J1
Jacobi, O1
Landman, Y1
Reinhorn, D1
Icht, O1
Sternschuss, M1
Rotem, O1
Finkel, I1
Allen, AM1
Dudnik, E1
Goldstein, DA1
Zer, A1
Ribeiro, AE1
Toporcov, TN1
Skinner, H2
Tsakiridis, T6
Santana-Davila, R1
Lu, B1
Erasmus, JJ1
Doemer, AJ1
Videtic, GMM1
Coster, J1
Yang, AX1
Lee, RY1
Werner-Wasik, M1
Schaner, PE1
McCormack, SE1
Esparaz, BT1
McGarry, RC1
Bazan, J1
Struve, T1
Paulus, R1
Bradley, JD1
Pond, GR1
Wright, J4
Ellis, PM1
Ahmed, N1
Abdulkarim, B1
Roa, W1
Robinson, A1
Swaminath, A2
Okawara, G1
Wierzbicki, M1
Valdes, M1
Levine, M1
Eze, C1
Belka, C1
Manapov, F1
Wang, JL1
Tsai, YT1
Lin, CH1
Cidem, A1
Staniczek, T1
Chang, GR1
Yen, CC1
Chong, KY1
Chen, CM1
Lin, J1
Gill, A1
Zahm, SH1
Carter, CA1
Shriver, CD1
Nations, JA1
Anderson, WF1
McGlynn, KA1
Zhu, K1
Mei, H1
Ding, Q1
Peng, G1
Tseng, CH1
Shimazu, K1
Tada, Y4
Morinaga, T1
Shingyoji, M1
Sekine, I4
Shimada, H1
Hiroshima, K1
Namiki, T1
Tatsumi, K4
Tagawa, M1
Pusceddu, S1
Prinzi, N1
Lo Russo, G1
Femia, D1
Milione, M1
Perrone, F1
Tamborini, E2
Concas, L1
Pulice, I1
Vernieri, C3
Corti, F1
Buzzoni, R1
de Braud, F2
Li, T1
Yi, E1
Henderson, D1
Frieson, D1
Zuber, J1
Solomon, SS1
Parikh, AB2
Kozuch, P1
Rohs, N1
Becker, DJ2
Levy, BP2
He, J1
Yan, H1
Cai, H1
Guan, Q1
Zheng, W1
Chen, R1
Song, K1
Guo, Z3
Tang, Q3
Zheng, F3
Xiao, Q1
Hann, SS3
Cruz-Bermúdez, A1
Vicente-Blanco, RJ1
Laza-Briviesca, R1
García-Grande, A1
Laine-Menéndez, S1
Gutiérrez, L1
Calvo, V1
Romero, A1
Martín-Acosta, P1
García, JM1
Provencio, M1
Yu, C1
Jiao, Y1
Xue, J1
Xing, L1
Zhu, W1
Chuang, MC1
Yang, YH1
Tsai, YH1
Hsieh, MJ1
Lin, YC1
Lin, CK1
Chen, PC1
Yang, TM1
Gupta, G1
de Jesus Andreoli Pinto, T1
Chellappan, DK1
Mishra, A1
Malipeddi, H1
Dua, K1
Roos, JF1
Qudsi, M1
Samara, A1
Rahim, MM1
Al-Bayedh, SA1
Ahmed, H1
Marrone, KA2
Forde, PM1
Purtell, M1
Brahmer, JR2
Hann, CL1
Kelly, RJ1
Coleman, B1
Gabrielson, E1
Rosner, GL1
Ettinger, DS2
Xin, WX1
Fang, L1
Fang, QL1
Zheng, XW1
Ding, HY1
Huang, P2
Xu, T2
Qiao, M1
Levy, A1
Doyen, J1
Kravets, S1
Dahlberg, SE1
Xie, F1
Qin, J1
Han, N1
Mao, W1
Moro, M2
Caiola, E2
Ganzinelli, M2
Zulato, E2
Rulli, E1
Marabese, M2
Centonze, G1
Busico, A1
Pastorino, U1
de Braud, FG1
Simbolo, M1
Bria, E1
Scarpa, A1
Indraccolo, S2
Broggini, M2
Sozzi, G2
Garassino, MC2
Kubo, T1
Ninomiya, T1
Hotta, K1
Kozuki, T1
Toyooka, S1
Okada, H1
Fujiwara, T1
Udono, H1
Kiura, K1
Zeng, S1
Gan, HX1
Xu, JX1
Liu, JY2
Pan, YH1
Lin, CY1
Lu, CH1
Wang, YB2
Chen, HY2
Wang, D2
Shao, C1
Tan, S1
Liang, F1
Wang, YG1
Wen-Xiu, X1
Xiao-Wei, Z1
Hai-Ying, D1
Ying-Hui, T1
Si-Si, K1
Xiao-Fang, Z1
Signorelli, D1
Galli, G1
Fabbri, A1
Hollander, L1
Gallucci, R1
Vandoni, G1
Gavazzi, C1
Triulzi, T1
Colombo, MP1
Rizzo, AM1
Corsetto, PA1
Pruneri, G1
Torri, V1
Liu, S1
Lin, X1
Xu, L1
Mao, X1
Zhang, Z1
Cho, EY1
Kim, HK1
Riaz, MA1
Sak, A1
Erol, YB1
Groneberg, M1
Thomale, J1
Stuschke, M1
Yao, L1
Liu, M1
Huang, X1
He, W1
Zhang, R2
Babbar, M1
Curtiss, CM1
Sheikh, MS1
Hung, LVM1
Moon, JY1
Ryu, JY1
Cho, SK1
Fillon, M1
Lai, SW1
Liao, KF1
Suissa, S2
Azoulay, L3
Lin, CC1
Yeh, HH1
Huang, WL1
Yan, JJ1
Lai, WW1
Su, WP1
Chen, HH1
Su, WC1
Popovich, IG1
Piskunova, TS1
Tyndyk, ML1
Anikin, IV1
Zabezhinskiĭ, MA1
Anisimov, VN1
Storozhuk, Y1
Hopmans, SN1
Sanli, T2
Barron, C1
Tsiani, E1
Cutz, JC2
Pond, G2
Singh, G2
Morgillo, F4
Sasso, FC4
Della Corte, CM4
Vitagliano, D1
D'Aiuto, E1
Troiani, T3
Martinelli, E3
De Vita, F2
Orditura, M2
De Palma, R1
Ciardiello, F4
Quinn, BJ1
Dallos, M1
Kitagawa, H1
Kunnumakkara, AB1
Memmott, RM2
Hollander, MC1
Gills, JJ1
Dennis, PA2
Guo, FC2
Shi, HS1
Wang, LQ1
Festino, L1
Manzo, A1
Capuano, A2
Dai, W1
Chu, X1
Yang, B1
Kitazono, S2
Takiguchi, Y3
Ashinuma, H2
Saito-Kitazono, M1
Kitamura, A2
Chiba, T2
Sakaida, E2
Kurosu, K2
Sakao, S1
Tanabe, N2
Iwama, A3
Yokosuka, O2
Ko, JC1
Chiu, HC3
Wo, TY2
Huang, YJ2
Tseng, SC2
Huang, YC2
Chen, HJ2
Syu, JJ1
Chen, CY1
Jian, YT1
Jian, YJ1
Lin, YW2
Xiao, H1
Li, K1
Izzotti, A1
Balansky, R1
D'Agostini, F1
Longobardi, M1
Cartiglia, C1
Micale, RT1
La Maestra, S1
Camoirano, A1
Ganchev, G1
Iltcheva, M1
Steele, VE2
De Flora, S1
Cheng, X1
Xiang, T1
He, L1
Long, H1
Zhu, B1
Zhang, ZJ3
Bi, Y1
Zhao, G1
Guo, Y1
Song, Q1
Liu, HB1
Shi, XF1
Mitrakas, AG1
Kalamida, D1
Koukourakis, MI1
Groenendijk, FH1
Mellema, WW1
van der Burg, E1
Schut, E1
Hauptmann, M1
Horlings, HM1
Willems, SM1
van den Heuvel, MM1
Jonkers, J1
Smit, EF1
Bernards, R1
Nie, SP1
Zhuang, MQ1
Lu, M1
Fasano, M2
Papaccio, F2
Berrino, L1
Tsai, MJ1
Yang, CJ1
Kung, YT1
Sheu, CC1
Shen, YT1
Chang, PY1
Huang, MS1
Sperl, B1
Ullrich, A1
Knyazev, P1
Schmedt, N1
Hense, S1
Hense, HW1
Geier, AS1
Lin, JJ1
Gallagher, EJ1
Sigel, K1
Mhango, G1
Galsky, MD1
Smith, CB1
LeRoith, D1
Wisnivesky, JP1
Randon, G1
Nardin, M1
Aliberti, C1
Pomerri, F1
Casarin, A1
Nicoletto, MO1
Sakoda, LC1
Ferrara, A1
Achacoso, NS1
Ehrlich, SF1
Quesenberry, CP1
Habel, LA1
Granja, S1
Marchiq, I1
Le Floch, R1
Moura, CS1
Baltazar, F1
Pouysségur, J1
O'Brien, AJ1
Villani, LA1
Broadfield, LA1
Houde, VP1
Galic, S1
Blandino, G1
Kemp, BE1
Muti, P1
Steinberg, GR1
Kong, F1
Zheng, R1
Yu, J1
Jia, Y1
Mutoh, M1
Ishikawa, H1
Liang, G1
Kowall, B1
Stang, A1
Rathmann, W1
Kostev, K1
Cao, H2
Shen, H2
Zhu, L2
Chu, Q1
Cao, M2
Sayed, R1
Saad, AS1
El Wakeel, L1
Elkholy, E1
Badary, O1
Tian, RH1
Zhang, YG1
Wu, Z1
Yang, JW1
Ji, HL1
Suwei, D1
Liang, Z1
Zhimin, L1
Ruilei, L1
Yingying, Z1
Zhen, L1
Chunlei, G1
Zhangchao, L1
Yuanbo, X1
Jinyan, Y1
Gaofeng, L1
Xin, S1
Deng, J1
Cao, N1
Geng, S1
Meng, M1
Lin, H1
Duan, Y1
Du, G1
Ciaramella, V1
Di Mauro, C1
Castellone, MD1
Bianco, R1
You, A1
Gao, J1
Fang, F1
Zhang, W1
Song, T1
Zhu, X1
Menamin, ÚC1
Cardwell, CR1
Hughes, CM1
Murray, LM1
Kurimoto, R1
Iwasawa, S1
Ebata, T1
Ishiwata, T1
Koide, S1
Nazim, UM1
Moon, JH1
Lee, JH2
Seol, JW1
Eo, SK1
Park, SY1
Arya, A1
Malecek, MK1
Shin, DS1
Carneiro, B1
Chandra, S1
Kaplan, J1
Kalyan, A1
Altman, JK1
Platanias, L1
Giles, F1
Lennon, FE1
Cianci, GC1
Kanteti, R1
Riehm, JJ1
Arif, Q1
Poroyko, VA1
Lupovitch, E1
Vigneswaran, W1
Husain, A1
Chen, P2
Liao, JK1
Sattler, M1
Kindler, HL1
Salgia, R1
Wan, G1
Yu, X1
Pan, D1
Cao, F1
Zhang, K1
Medairos, RA1
Clark, J1
Holoubek, S1
Kubasiak, JC1
Pithadia, R1
Hamid, F1
Chmielewski, GW1
Warren, WH1
Basu, S1
Borgia, JA1
Liptay, MJ1
Seder, CW1
Luo, J1
Hendryx, M1
Qi, L1
Ho, GY1
Margolis, KL1
Kim, S1
Qu, X1
Varela-Santoyo, E1
Soto-Perez-de-Celis, E1
Sánchez-Reyes, R1
De la Torre-Vallejo, M1
Muñiz-Hernández, S1
Wu, H1
Walker, J1
Damhuis, RA1
Brewster, DH1
Wild, SH1
Watarai, H1
Okada, M1
Kuramoto, K1
Takeda, H1
Sakaki, H1
Suzuki, S1
Seino, S1
Oizumi, H1
Sadahiro, M1
Kitanaka, C1
Hou, XB1
Li, TH1
Ren, ZP1
Xiong, Y1
Miao, L2
Lin, CM1
Huang, L2
Seabloom, DE1
Galbraith, AR1
Haynes, AM1
Antonides, JD1
Wuertz, BR1
Miller, WA1
Miller, KA1
Miller, MS1
Clapper, ML1
O'Sullivan, MG1
Li, KL1
Shi, K1
Satterlee, A1
Haynes, M1
Luo, C1
Musetti, S1
Pellegrinotti, M1
Fimognari, FL1
Franco, A1
Repetto, L1
Pastorelli, R1
Phoenix, KN1
Vumbaca, F1
Fox, MM1
Evans, R1
Claffey, KP1
Rashid, A1
Harding, S1
Bristow, RG1
Engelman, JA1
Cantley, LC1
Mercado, JR1
Maier, CR1
Kawabata, S1
Fox, SD1
Liu, JL1
Mao, Z1
Gallick, GE1
Yung, WK1
Antonoff, MB1
D'Cunha, J1
Iliopoulos, D1
Hirsch, HA1
Struhl, K1
Tan, BX1
Yao, WX1
Peng, XC1
Du, XB1
Yao, B1
Xie, K1
Li, LH1
Dong, H1
Zhao, F1
Hou, JM1
Su, JM1
Rattan, R1
Graham, RP1
Maguire, JL1
Giri, S1
Shridhar, V1
Wu, N1
Gu, C1
Gu, H1
Han, Y1
Salani, B1
Maffioli, S1
Hamoudane, M1
Parodi, A1
Ravera, S1
Passalacqua, M1
Alama, A1
Nhiri, M1
Cordera, R1
Maggi, D1
Kitazono-Saitoh, M1
Smiechowski, BB1
Yin, H1
Pollak, MN1
Bodmer, M1
Becker, C1
Jick, SS1
Meier, CR1
Mazzone, PJ1
Rai, H1
Beukemann, M1
Jain, A1
Sasidhar, M1
Weng, SH1
Ihle, NT1
Paine-Murrieta, G1
Berggren, MI1
Baker, A1
Tate, WR1
Wipf, P1
Abraham, RT1
Kirkpatrick, DL1
Powis, G1
Algire, C1
Zakikhani, M1
Blouin, MJ1
Shuai, JH1
Pollak, M1
Laursen, B1
Gormsen, J1

Clinical Trials (14)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy[NCT02514447]Phase 1/Phase 2123 participants (Actual)Interventional2015-10-05Terminated (stopped due to Primary Analysis and survival follow up completed per protocol. Not stopped due to safety concerns.)
Tumor Mutation Status Will Predict Metabolic Response to Metformin in Non Small Cell Lung Cancer (NSCLC)[NCT02285855]Phase 227 participants (Actual)Interventional2015-02-20Terminated (stopped due to Poor Accrual)
Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC[NCT02186847]Phase 2170 participants (Actual)Interventional2014-08-31Active, not recruiting
A Phase II Study to Investigate a Combination of Metformin With Chemo-Radiotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer[NCT02115464]Phase 254 participants (Actual)Interventional2014-12-17Terminated (stopped due to The accrual rate was not high enough to reach the target sample size.)
A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Previously Untreated Advanced/Metastatic Pulmonary Adenocarcinoma[NCT01578551]Phase 225 participants (Actual)Interventional2012-05-31Terminated (stopped due to Low enrollment)
An Open-Label Single-Arm Phase Ⅱ Study to Evaluate Efficacy and Safety of Sintilimab Combined With Metformin Hydrochloride in Patients With Advanced Non-small Cell Lung Cancer Refractory to First-Line Treatment[NCT03874000]Phase 243 participants (Anticipated)Interventional2019-03-08Recruiting
Safety of Lanreotide 120 mg ATG in Combination With Metformin in Patients With Progressive Advanced Well-differentiated Gastro-intestinal (GI) or Lung Carcinoids: A Pilot, One-arm, Open-label, Prospective Study: the MetNET-2 Trial[NCT02823691]Early Phase 120 participants (Actual)Interventional2016-04-30Active, not recruiting
Effect of Metformin in Combination With Tyrosine Kinase Inhibitors (TKI) on Clinical, Biochemical and Nutritional in Patients With Non-Small Cell Lung Carcinoma (NSCLC): Randomized Clinical Trial[NCT03071705]120 participants (Anticipated)Interventional2016-03-31Recruiting
Prospective Observational Trial to Evaluate the Efficacy of the Combination of Osimertinib and Aspirin in Patients With Disease Progression to 1st Generation EGFR-TKI Due to Acquisition of EGFR T790M[NCT03543683]330 participants (Anticipated)Observational2020-08-01Not yet recruiting
Prospective Observational Trial to Evaluate the Efficacy of the Combination of Osimertinib and Aspirin in Patients With Epidermal Growth Factor Receptor(EGFR)-Mutation[NCT04184921]350 participants (Anticipated)Observational2020-08-01Not yet recruiting
Prospective Observational Trial to Evaluate the Efficacy of the Combination of Osimertinib and Aspirin in Patients With Disease Progression to 3st Generation Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor（EGFR-TKI） Osimertinib[NCT03532698]100 participants (Anticipated)Observational2020-08-01Not yet recruiting
Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Melanoma, breAst or Lung Cancer Patients With Brain Metastases: the Phase II OPTIMAL Study[NCT04001725]Phase 2110 participants (Anticipated)Interventional2019-10-15Recruiting
Metformin Pharmacology in Human Cancers[NCT03477162]Early Phase 118 participants (Actual)Interventional2018-05-15Terminated (stopped due to Enrollment was closed as efforts had become more challenging, and the lab indicated that they were able to obtain their primary objective with the number that had already been enrolled.)
A Phase II, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination of Gefitinib and Metformin in Patients With Locally Advanced and Metastatic Non-Small-Cell-Lung-Cancer[NCT01864681]Phase 2224 participants (Actual)Interventional2013-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Assess the Dose Limiting Toxicities (DLTs) of G1T28/Trilaciclib Administered With Topotecan in Part 1

"The percentage of patients experiencing DLTs in Part 1 of the study in each cohort, including:~Absolute neutrophil count (ANC) < 0.5 × 10^9/L lasting for ≥ 7 days~≥ Grade 3 neutropenic infection/febrile neutropenia~Grade 4 thrombocytopenia or ≥ Grade 3 thrombocytopenia with bleeding~Unable to start next cycle of chemotherapy due to lack of recovery to an ANC ≥ 1.5 × 10^9/L and platelet count ≥ 100 × 10^9/L; a delay of up to 1 week from the scheduled start of Cycle 2 is allowed for recovery of ANC and platelet count, and is not considered a DLT~≥ Grade 3 nonhematologic toxicity (nausea, vomiting, and diarrhea failing maximal medical management; fatigue lasting for > 72 hours)" (NCT02514447)
Timeframe: Evaluated for Cycle 1 (i.e., from date of first dose of study drug (Part 1) to the end of Cycle 1, each cycle = 21 days)

InterventionParticipants (Count of Participants)
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m²- Part 1 Cohort 12
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m²- Part 1 Cohort 22
Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m²- Part 1 Cohort 32
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m²- Part 1 Cohorts 4 and 60
Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m²- Part 1 Cohort 52
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m²- Part 1 Cohort 72

Assess the Hematologic Profile of G1T28/Trilaciclib Administered With Topotecan

The weekly event rate of Major Adverse Hematologic Events (MAHE) events (NCT02514447)
Timeframe: During the treatment period. From date of first dose (Part 1)/randomization (Part 2), 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator (assessed up to 1090 days).

Interventionevents per participant/week (Number)
Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b0.258
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a0.091
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b0.102
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 10.403
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 10.156
Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 10.102
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 10.037
Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 10.085
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 10.073

Chemotherapy Exposure

Average duration of exposure to chemotherapy (topotecan) in days. (NCT02514447)
Timeframe: During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator (assessed up to a maximum of 1335 days).

Interventiondays (Mean)
Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b94
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a110
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b109
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 1147
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 1147
Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 1102
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 1124
Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 178
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 183

Dose Reductions in Chemotherapy (Topotecan)

Overall event rate of dose reductions in chemotherapy (topotecan) (NCT02514447)
Timeframe: During the treatment period. From date of first dose (Part 1)/randomization (Part 2), 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator (assessed up to 1090 days).

Interventionevents per participant per cycle (Number)
Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b0.116
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a0.053
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b0.051
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 10.500
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 10.250
Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 10.118
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 10.089
Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 10.040
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 10.036

Duration of Response (DOR)

The median months and 95% CIs of duration of response. (NCT02514447)
Timeframe: From date of first dose of study drug (Part 1)/randomization (Part 2) until the occurrence of progressive disease, withdrawal of consent, or initiation of subsequent anti-cancer therapy, (assessed up to a maximum of 1335 days).

Interventionmonths (Median)
Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b4.9
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a7.8
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b6.8
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 1NA
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 15.4
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 16.7
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 1NA

Duration of Severe (Grade 4) Neutropenia in Cycle 1

Duration of severe neutropenia (DSN; days) was defined as the number of days from the date of the first ANC value of <0.5 × 10^9/L observed between start of cycle and end of cycle to the date of the first ANC value ≥0.5 × 10^9/L that met the following criteria: (1) occurred after the ANC value of <0.5 × 10^9/L and (2) no other ANC values <0.5 × 10^9/L occurred between this day and end of cycle. DSN is set to 0 for patients who did not experience SN in a cycle, including those who were randomized but never treated. Data from unscheduled visits and the actual assessment date (rather than visit date) were included in the derivation. (NCT02514447)
Timeframe: Evaluated for Cycle 1 (i.e., from date of first dose of study drug (Part 1)/randomization (Part 2) to the end of Cycle 1, each cycle = 21 days)

Interventiondays (Mean)
Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b8
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a1
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b2
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 114
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 18
Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 10
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 10
Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 12
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 13

Need for Treatment With Hematopoietic Growth Factors

Percentage of patients requiring G-CSF administration. (NCT02514447)
Timeframe: During the treatment period. From date of first dose (Part 1)/randomization (Part 2), 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator (assessed up to 1090 days).

InterventionParticipants (Count of Participants)
Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b19
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a8
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b16
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 12
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 12
Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 11
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 14
Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 12
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 13

Occurrence of Erythropoietin-stimulating Agent (ESA) Administrations

The count of patients who received any ESA administration. (NCT02514447)
Timeframe: During the treatment period. From date of first dose (Part 1)/randomization (Part 2), 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator (assessed up to 1090 days).

InterventionParticipants (Count of Participants)
Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b6
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a5
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b1
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 12
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 11
Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 10
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 11
Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 10
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 11

Occurrence of Febrile Neutropenia Adverse Events

Percentage of patients who experience febrile neutropenia adverse events (NCT02514447)
Timeframe: During the treatment period. From date of first dose (Part 1)/randomization (Part 2), 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator (assessed up to 1090 days).

InterventionParticipants (Count of Participants)
Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b5
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a1
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b2
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 10
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 10
Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 10
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 10
Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 11
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 10

Occurrence of Grade 3 and 4 Hematologic Toxicities

The count of patients with any hematologic lab value that meets the CTCAE toxicity grade criteria for ≥ Grade 3 and the value is treatment emergent (occurs after first dose of study drug). Labs include: Hemoglobin (HGB), hematocrit, white blood cell (WBC), platelet counts, ANC, ALC, Monocyte Absolute, Basophil Absolute, and Eosinophil Absolute. (NCT02514447)
Timeframe: During the treatment period. From date of first dose (Part 1)/randomization (Part 2), 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator (assessed up to 1090 days).

InterventionParticipants (Count of Participants)
Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b27
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a25
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b29
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 12
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 13
Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 14
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 17
Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 17
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 17

Occurrence of Infection Serious Adverse Events (SAEs)

Percentage of patients experiencing an SAE that codes to the Medical Dictionary for Regulatory Activities (MedDRA) system organ class (SOC) of Infections and Infestations (NCT02514447)
Timeframe: During the treatment period. From date of first dose (Part 1)/randomization (Part 2), 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator (assessed up to 1090 days).

InterventionParticipants (Count of Participants)
Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b3
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a2
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b1
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 12
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 11
Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 11
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 10
Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 10
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 11

Occurrence of Intravenous (IV) Antibiotic Use

Percentage of patients requiring systemic/IV antibiotics (NCT02514447)
Timeframe: During the treatment period. From date of first dose (Part 1)/randomization (Part 2), 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator (assessed up to 1090 days).

InterventionParticipants (Count of Participants)
Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b8
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a8
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b7
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 12
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 11
Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 11
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 11
Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 12
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 11

Occurrence of Platelet Transfusions

Percentage of patients requiring a platelet transfusion (NCT02514447)
Timeframe: During the treatment period. From date of first dose (Part 1)/randomization (Part 2), 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator (assessed up to 1090 days).

InterventionParticipants (Count of Participants)
Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b9
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a4
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b8
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 10
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 11
Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 10
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 10
Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 11
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 10

Occurrence of Pulmonary Infection Serious Adverse Events (SAEs)

Percentage of patients experiencing an SAE that codes to the Medical Dictionary for Regulatory Activities (MedDRA) system organ class (SOC) of Infections and Infestations and falls into a preferred term (PT) categorized as a pulmonary infection custom MedDRA query (CMQ) (NCT02514447)
Timeframe: During the treatment period. From date of first dose (Part 1)/randomization (Part 2), 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator (assessed up to 1090 days).

InterventionParticipants (Count of Participants)
Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b1
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a1
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b1
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 11
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 11
Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 11
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 10
Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 10
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 11

Occurrence of RBC Transfusions

Percentage of patients requiring a RBC transfusion on/after week 5 (NCT02514447)
Timeframe: During the treatment period. From date of first dose (Part 1)/randomization (Part 2), 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator (assessed up to 1056 days).

InterventionParticipants (Count of Participants)
Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b12
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a5
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b10
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 12
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 11
Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 12
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 11
Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 11
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 12

Occurrence of Severe (Grade 4) Neutropenia

Number of Participants with severe (Grade 4) neutropenia (SN) was a binary variable. If a patient had at least 1 absolute neutrophil count value <0.5 × 10^9/L during the Treatment Period, the patient was assigned as Yes to the occurrence of SN; otherwise, it was No. (NCT02514447)
Timeframe: During the treatment period. From date of first dose (Part 1)/randomization (Part 2), 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator (assessed up to 1090 days).

InterventionParticipants (Count of Participants)
Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b22
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a5
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b13
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 12
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 12
Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 11
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 10
Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 12
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 13

Overall Survival (OS)

Median time (months) and 95% CI from date of first dose date of study drug/randomization until date of death. Patients who do not die during the study will be censored at the date last known to be alive. (NCT02514447)
Timeframe: From date of first dose of study drug (Part 1)/randomization (Part 2) until the date of death due to any cause (evaluated up to a maximum of 2220 days).

Interventionmonths (Median)
Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b6.5
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a5.8
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b6.2
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 1NA
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 110.6
Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 18.3
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 19.4
Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 14.4
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 110.0

Pharmacokinetic Profile for Topotecan When Administered With Trilaciclib (G1T28)

Maximum concentration (Cmax) of topotecan when administered with trilaciclib (G1T28) (NCT02514447)
Timeframe: Part 1 of the study during Cycle 1 Day 4 : predose, 0.5, 1, 1.5, 2, 2.5, 3, 4.5, 6.5, 8.5 (optional), and 24.5 hours post dose. Part 2 of the study during Cycle 1 Day 4 : predose, 0.5, 1, between 3 to 4 hours and between 5.5 to 6.5 hours post dose.

Interventionng/ml (Geometric Mean)
Trilaciclib (G1T28) + Topotecan 0.75 mg/m²- Part 121.1
Trilaciclib (G1T28) + Topotecan 1 mg/m²- Part 136.8
Trilaciclib (G1T28) + Topotecan 1.25 mg/m²- Part 152.4
Trilaciclib (G1T28) + Topotecan 1.50 mg/m²- Part 1NA
Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b43.0
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a17.5
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b41.4

Pharmacokinetic Profile for Trilaciclib (G1T28) When Administered With Topotecan

Maximum concentration (Cmax) of trilaciclib (G1T28) when administered with topotecan (NCT02514447)
Timeframe: Part 1 of the study during Cycle 1 Day 4 : predose, 0.5, 1, 1.5, 2, 2.5, 3, 4.5, 6.5, 8.5 (optional), and 24.5 hours post dose. Part 2 of the study during Cycle 1 Day 4 : predose, 0.5, 1, between 3 to 4 hours and between 5.5 to 6.5 hours post dose.

Interventionng/ml (Geometric Mean)
Trilaciclib (G1T28) 200 mg/m² + Topotecan - Part 11060
Trilaciclib (G1T28) 240 mg/m² + Topotecan - Part 11220
Trilaciclib (G1T28) 280 mg/m² + Topotecan - Part 12220
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a913
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b1100

Progression Free Survival (PFS)

"Median time (months) and 95% CI from date of first dose of study drug/randomization until date of documented disease progression or death due to any cause.~Investigators followed the Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 guidelines for tumor assessments to determine progression. Progressive Disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression)." (NCT02514447)
Timeframe: From date of first dose of study drug (Part 1)/randomization (Part 2), until date of documented disease progression or death due to any cause (evaluated up to a maximum of 1335 days).

Interventionmonths (Median)
Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b4.2
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a3.0
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b4.2
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 15.5
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 14.3
Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 13.6
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 14.5
Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 11.8
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 12.1

Chemotherapy Cycles and Modifications Overall

Average exposure and cycle modifications in chemotherapy (topotecan) (NCT02514447)
Timeframe: During the treatment period. From date of first dose, 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator (assessed up to a maximum of 1335 days).

,,,,,,,,
Interventioncycles (Mean)
Number of cycles completedNumber of cycles delayed
Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b41
Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 141
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 171
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 163
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 161
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a52
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 141
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b51
Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 140

Occurrence of Grade 4 and Grade 3/4 Decreased Platelet Count Laboratory Values (Thrombocytopenia)

The count of patients with any platelet lab value that meets the CTCAE toxicity grade criteria for ≥ Grade 3 and the value is treatment emergent (occurs after first dose of study drug). (NCT02514447)
Timeframe: During the treatment period. From date of first dose (Part 1)/randomization (Part 2), 21 day treatment cycles continue until disease progression, unacceptable toxicity, or discontinuation by the patient or investigator (assessed up to 1090 days).

,,,,,,,,
InterventionParticipants (Count of Participants)
Overall Grade 3/4 ThrombocytopeniaOverall Grade 4 Thrombocytopenia
Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b1911
Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 132
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 121
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 122
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 120
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a159
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 141
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b2113
Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 142

Tumor Response Based on RECIST, Version 1.1

"The percentage of patients who fall into each category of Best overall response (BOR) as defined by RECIST, Version 1.1.~Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions.~Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions.~Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.~When no imaging/measurement is done, the patient is not evaluable (NE); and if only a subset of lesion measurements are made, usually the case is also considered NE." (NCT02514447)
Timeframe: From date of first dose of study drug (Part 1)/randomization (Part 2) until the occurrence of progressive disease, withdrawal of consent, or initiation of subsequent anti-cancer therapy, (assessed up to a maximum of 1335 days).

,,,,,,,,
InterventionParticipants (Count of Participants)
Complete Response (CR)Partial Response (PR)Stable Disease (SD)Progressive Disease (PD)Not Evaluable (NE)No post-baseline tumor assessment (Missing)
Placebo + Topotecan 1.5 mg/m² - Parts 2a and 2b1510622
Trilaciclib (G1T28) 200 mg/m² + Topotecan 0.75 mg/m² - Cohort 3- Part 1003100
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.25 mg/m² - Cohort 2- Part 1020100
Trilaciclib (G1T28) 200 mg/m² + Topotecan 1.5 mg/m² - Cohort 1- Part 1011000
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Cohorts 4 and 6- Part 1016100
Trilaciclib (G1T28) 240 mg/m² + Topotecan 0.75 mg/m² - Part 2a0315902
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.0 mg/m² - Cohort 7- Part 1013201
Trilaciclib (G1T28) 240 mg/m² + Topotecan 1.5 mg/m² - Part 2b0513606
Trilaciclib (G1T28) 280 mg/m² + Topotecan 0.75 mg/m² - Cohort 5- Part 1003201

RECIST and PERCIST Tumor Response

The primary objective is the effect of metformin on response in NSCLC patients treated with hypofractionated RT. All patients will receive FDG-PET/CT scan at baseline (prior to metformin start), prior to RT and at 6 months (+/- 30 days) following RT. PET/CT imaging using [18F]-2-fluoro-2-deoxyglucose positron emission tomography (18F-FDG), using a standard approved radiopharmaceutical dose and administration selected by the nuclear medicine physician (120 min). Response will be determined at 6 months post-treatment via relative change from pre-treatment tumor by Response Evaluation Criteria in Solid Tumor (RECIST) by complete response (CR), partial response (PR) and stable disease (SD) and PET Response Criteria in Solid Tumors (PERCIST) by stable metabolic disease (SMD), progressive metabolic disease (PMD) and complete metabolic response(CMR). (NCT02285855)
Timeframe: From baseline (prior to metformin start) to Post-Radiotherapy (RT) Treatment, assessed up to 6 months

,
InterventionParticipants (Count of Participants)
Mid-treatment RECIST tumor response (SD)Post-treatment (6 mo.) RECIST tumor response(CR)Post-treatment (6 mo.) RECIST tumor response(PR)Post-treatment (6 mo.) RECIST tumor response(SD)Mid-treamtment PERCIST tumor response: (SMD)Mid-treamtment PERCIST tumor response: (PMD)Mid-treamtment PERCIST tumor response: (PMR)Post- treatment (6 mo.) PERCIST (CMR)Post- treatment (6 mo.) PERCIST (PMD)Post- treatment (6 mo.) PERCIST (PMR)
Metformin Arm14733662913
Placebo Arm1100100100

Percentage of Participants Alive (Overall Survival)

Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated using the Kaplan-Meier method. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. One-year rates are provided. Analysis occurred after 102 progression-free survival events were reported. (NCT02186847)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 47.2 months.

Interventionpercentage of participants (Number)
Chemoradiation38.5
Metformin + Chemoradiation40.1

Percentage of Participants Alive Without Progression (Progression-free Survival)

Progression is defined per RECIST v1.1 as change in a known lesion(s) meeting one of the following criteria: [1] At least a 20% increase in the sum of the longest diameter of target lesions such that the absolute increase must be > 5 mm. [2] Appearance of ≥1 new lesions. Progression-free survival time is defined as time from randomization to the date of first progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. One-year rates are provided. Analysis occurred after 102 progression-free survival events were reported. (NCT02186847)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 47.2 months.

Interventionpercentage of participants (Number)
Chemoradiation60.4
Metformin + Chemoradiation51.3

Percentage of Participants With Distant Metastases

Distant metastasis (DM) is defined as the appearance of ≥ 1 new lesions at any site (including pleural or pericardial effusion) outside of the following: the planned treatment volume, the same lobe(s) of the lung as the primary tumor, or regional lymph nodes. Time to DM is defined as time from randomization to the date of first DM, death without DM (competing risk), or last known follow-up (censored). DM rates are estimated using the cumulative incidence method. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. One-year rates are provided. Analysis occurred after 102 progression-free survival events were reported. (NCT02186847)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 47.2 months.

Interventionpercentage of participants (Number)
Chemoradiation17.2
Metformin + Chemoradiation20.5

Percentage of Participants With Local-regional Progression

Local-regional progression (LRP) is defined as progression within the planned treatment volume (PTV) or outside the PTV but within the same lobe(s) of the lung as the primary tumor or in regional lymph nodes. Progression is defined as change in a known lesion(s) meeting one of the following criteria: [1] ≥ 20% increase in the sum of the longest diameter of target lesions such that the absolute increase must be > 5 mm. [2] Appearance of ≥1 new lesions. LRP time is defined as time from randomization to the date of first LRP, death without LRP (competing risk), or last known follow-up (censored). LRP rates are estimated using the cumulative incidence method. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. One-year rates are provided. Analysis occurred after 102 LRP events were reported. (NCT02186847)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 47.2 months.

Interventionpercentage of participants (Number)
Chemoradiation17.2
Metformin + Chemoradiation20.5

Percentage of Participants With Treatment-related Grade 3 or Higher Adverse Events

"Adverse events (AE) were graded using the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Grade refers to the severity of the AE. The CTCAE v4.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild, Grade 2 Moderate, Grade 3 Severe, Grade 4 Life-threatening or disabling, Grade 5 Death related to adverse event. Treatment-related is defined definitely, probably, or possibly related to treatment." (NCT02186847)
Timeframe: From start of treatment to last follow-up. Maximum follow-up at time of analysis was 47.2 months.

Interventionpercentage of participants (Number)
Chemoradiation67.1
Metformin + Chemoradiation63.4

Overall Survial

Number of months alive after 1 year of the combination of metformin with standard chemotherapy in patients with previously untreated advanced or metastatic pulmonary adenocarcinoma. (NCT01578551)
Timeframe: up to 2 years

Interventionmonths (Median)
Arm A15.9
Arm B13.9

Progression Free Survival (PFS)

Number of months without evidence of progression after 1 year of the combination of metformin and standard chemotherapy in patients with previously untreated advanced or metastatic pulmonary adenocarcinoma. (NCT01578551)
Timeframe: 1 year

Interventionmonths (Median)
Arm A9.6
Arm B6.7

Response to Therapy

Percentage of participants with complete or partial response to combination of metformin with standard chemotherapy in patients with previously untreated advanced or metastatic pulmonary adenocarcinoma as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (NCT01578551)
Timeframe: 2 years

Interventionpercentage of participants (Number)
Arm A56
Arm B33

Concentration of Metformin in Adipose Tissue

To determine the concentration of metformin in adipose tissue. (NCT03477162)
Timeframe: Within 7 days from surgery

Interventionng/g (Median)
Metformin70

Concentration of Metformin in Plasma.

To determine the concentration of metformin in plasma. (NCT03477162)
Timeframe: Within 7 days from surgery

Interventionng/mL (Median)
Metformin450

Concentration of Metformin in Tumor-adjacent Normal Tissue

To determine the concentration of metformin in tumor-adjacent normal tissue. (NCT03477162)
Timeframe: Within 7 days from surgery

Interventionng/g (Median)
Metformin749

Concentration of Metformin in Whole Blood.

To determine the concentration of metformin in whole blood. (NCT03477162)
Timeframe: Within 7 days from surgery

Interventionng/mL (Median)
Metformin514

Lung Tumor Tissue Concentration of Metformin

To determine the intra-tumor concentrations of metformin, with a standard deviation ≤25% of the mean, in patients with solid tumors of thoracic origin administered metformin extended release. (NCT03477162)
Timeframe: Within 7 days from surgery

Interventionng/g (Median)
Metformin1290

Reviews

22 reviews available for metformin and Cancer of Lung

ArticleYear
Advances in metformin‑based metabolic therapy for non‑small cell lung cancer (Review).
    Oncology reports, 2022, Volume: 47, Issue:3

    Topics: Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Therapy, Combination; Glycolysis; Humans; H

2022
Combined regimens of cisplatin and metformin in cancer therapy: A systematic review and meta-analysis.
    Life sciences, 2022, Sep-01, Volume: 304

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; L

2022
Research progress on the therapeutic effect and mechanism of metformin for lung cancer (Review).
    Oncology reports, 2023, Volume: 49, Issue:1

    Topics: Aged; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lung Neoplasms; Metformin; Middle Aged

2023
[Research Advance in Anti-lung Cancer Mechanism of Metformin].
    Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2020, Apr-20, Volume: 23, Issue:4

    Topics: Animals; Antineoplastic Agents; Humans; Lung Neoplasms; Metformin

2020
The effect of metformin on lung cancer risk and survival in patients with type 2 diabetes mellitus: A meta-analysis.
    Journal of clinical pharmacy and therapeutics, 2020, Volume: 45, Issue:4

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Lung Neoplasms; Metformin

2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Molecular mechanisms underlining the role of metformin as a therapeutic agent in lung cancer.
    Cellular oncology (Dordrecht), 2021, Volume: 44, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Humans; Lung Neoplasms; Metformin; Neoplasm Proteins; Sig

2021
Metformin improves survival in patients with concurrent diabetes and small cell lung cancer: a meta-analysis.
    Minerva endocrinology, 2023, Volume: 48, Issue:2

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lung Neoplasms; Metformin; Small Cell Lung C

2023
The role of metformin on lung cancer survival: the first systematic review and meta-analysis of observational studies and randomized clinical trials.
    Journal of cancer research and clinical oncology, 2021, Volume: 147, Issue:10

    Topics: Humans; Hypoglycemic Agents; Lung Neoplasms; Metformin; Observational Studies as Topic; Prognosis; R

2021
A clinical update on metformin and lung cancer in diabetic patients.
    Panminerva medica, 2018, Volume: 60, Issue:2

    Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Cell Cycle; Clinical Trials as T

2018
Metformin for lung cancer prevention and improved survival: a novel approach.
    European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2019, Volume: 28, Issue:4

    Topics: Carcinogenesis; Carcinogens; Diabetes Mellitus, Type 2; Gene Expression Regulation, Neoplastic; Huma

2019
Effect of hypoglycemic agents on survival outcomes of lung cancer patients with diabetes mellitus: A meta-analysis.
    Medicine, 2018, Volume: 97, Issue:9

    Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Lung Neo

2018
Metformin for non-small cell lung cancer patients: Opportunities and pitfalls.
    Critical reviews in oncology/hematology, 2018, Volume: 125

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Humans; Hypoglycemic Agent

2018
Metformin improves survival in lung cancer patients with type 2 diabetes mellitus: A meta-analysis.
    Medicina clinica, 2019, 04-18, Volume: 152, Issue:8

    Topics: Aged; Carcinoma, Non-Small-Cell Lung; China; Confidence Intervals; Diabetes Mellitus, Type 2; Humans

2019
Metformin Use and Lung Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis.
    Disease markers, 2019, Volume: 2019

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lung Neoplasms; Metformin

2019
Metformin in lung cancer: rationale for a combination therapy.
    Expert opinion on investigational drugs, 2013, Volume: 22, Issue:11

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small

2013
Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis.
    American journal of epidemiology, 2014, Jul-01, Volume: 180, Issue:1

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lung Neoplasms; Metformin; Risk; Risk Factor

2014
Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Lung Neoplasms; Metformin; Publicat

2014
Anti-diabetic medications do not influence risk of lung cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:16

    Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin; Lung Neoplasms; Metformin; Sulfonylurea Com

2014
Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: a meta-analysis.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2016, Volume: 18, Issue:6

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lung Neoplasms; Metformin; Prognosis

2016
Repurposing metformin for cancer treatment: current clinical studies.
    Oncotarget, 2016, Jun-28, Volume: 7, Issue:26

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Clinical Trials as Topic; Coho

2016
Metformin therapy associated with survival benefit in lung cancer patients with diabetes.
    Oncotarget, 2016, Jun-07, Volume: 7, Issue:23

    Topics: Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agents; Lung Neoplasms; Metformin

2016

Trials

18 trials available for metformin and Cancer of Lung

ArticleYear
Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial.
    JAMA oncology, 2022, 03-01, Volume: 8, Issue:3

    Topics: Adenocarcinoma of Lung; Body Mass Index; ErbB Receptors; Humans; Lung Neoplasms; Metformin; Mutation

2022
Pharmacokinetic Drug-Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer.
    Clinical drug investigation, 2022, Volume: 42, Issue:8

    Topics: Area Under Curve; Drug Interactions; Healthy Volunteers; Humans; Itraconazole; Lung Neoplasms; Metfo

2022
A phase II study of metformin plus pemetrexed and carboplatin in patients with non-squamous non-small cell lung cancer (METALUNG).
    Medical oncology (Northwood, London, England), 2023, Jun-01, Volume: 40, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans;

2023
Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 12-01, Volume: 25, Issue:23

    Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-

2019
Metabolic Responses to Metformin in Inoperable Early-stage Non-Small Cell Lung Cancer Treated With Stereotactic Radiotherapy: Results of a Randomized Phase II Clinical Trial.
    American journal of clinical oncology, 2020, Volume: 43, Issue:4

    Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Glucose; Humans; Hypoglycemic Agent

2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2021, Volume: 151

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diet; D

2021
Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non-Small Cell Lung Cancer: The NRG-LU001 Phase 2 Randomized Clinical Trial.
    JAMA oncology, 2021, Sep-01, Volume: 7, Issue:9

    Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Humans; Lung Neoplasms; Male; Metfo

2021
Metformin in Combination With Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical Trial.
    JAMA oncology, 2021, Sep-01, Volume: 7, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; F

2021
Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial.
    Investigational new drugs, 2017, Volume: 35, Issue:6

    Topics: Aged; Carcinoma, Non-Small-Cell Lung; Drug Repositioning; Female; Follow-Up Studies; Humans; Hypogly

2017
A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
    The oncologist, 2018, Volume: 23, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, No

2018
Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors.
    Clinical lung cancer, 2018, Volume: 19, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Comb

2018
Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial.
    Clinical lung cancer, 2019, Volume: 20, Issue:3

    Topics: Adenocarcinoma of Lung; Adolescent; Adult; Aged; AMP-Activated Protein Kinase Kinases; Antineoplasti

2019
A pooled analysis of two phase II trials evaluating metformin plus platinum-based chemotherapy in advanced non-small cell lung cancer.
    Cancer treatment and research communications, 2019, Volume: 20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female;

2019
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
    International journal of cancer, 2015, Mar-15, Volume: 136, Issue:6

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein

2015
A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial.
    Clinical lung cancer, 2015, Volume: 16, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small

2015
Metformin Addition to Chemotherapy in Stage IV Non-Small Cell Lung Cancer: an Open Label Randomized Controlled Study.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:15

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat

2015
A Multicenter Double-blind Phase II Study of Metformin With Gefitinib as First-line Therapy of Locally Advanced Non-Small-cell Lung Cancer.
    Clinical lung cancer, 2017, Volume: 18, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China;

2017

Other Studies

171 other studies available for metformin and Cancer of Lung

ArticleYear
Petasin potently inhibits mitochondrial complex I-based metabolism that supports tumor growth and metastasis.
    The Journal of clinical investigation, 2021, 09-01, Volume: 131, Issue:17

    Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Electron Trans

2021
Metformin inhibits human non-small cell lung cancer by regulating AMPK-CEBPB-PDL1 signaling pathway.
    Cancer immunology, immunotherapy : CII, 2022, Volume: 71, Issue:7

    Topics: AMP-Activated Protein Kinases; Animals; Carcinoma, Non-Small-Cell Lung; CCAAT-Enhancer-Binding Prote

2022
Radiotherapy and high bilirubin may be metformin like effect on lung cancer via possible AMPK pathway modulation.
    Bratislavske lekarske listy, 2022, Volume: 123, Issue:2

    Topics: AMP-Activated Protein Kinases; Bilirubin; Humans; Lung Neoplasms; Metformin; Retrospective Studies;

2022
Development of a Magnetic Nanostructure for Co-delivery of Metformin and Silibinin on Growth of Lung Cancer Cells: Possible Action Through Leptin Gene and its Receptor Regulation.
    Asian Pacific journal of cancer prevention : APJCP, 2022, Feb-01, Volume: 23, Issue:2

    Topics: A549 Cells; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Gene Expression R

2022
Metformin increases the radiosensitivity of non-small cell lung cancer cells by destabilizing NRF2.
    Biochemical pharmacology, 2022, Volume: 199

    Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Kelch-Like ECH-Associated Protein 1; Lung

2022
Identification of patient characteristics associated with survival benefit from metformin treatment in patients with stage I non-small cell lung cancer.
    The Journal of thoracic and cardiovascular surgery, 2022, Volume: 164, Issue:5

    Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Male; Metformin; Neoplasm Staging; Proportio

2022
Metformin combined with local irradiation provokes abscopal effects in a murine rectal cancer model.
    Scientific reports, 2022, 05-04, Volume: 12, Issue:1

    Topics: Animals; CD8-Positive T-Lymphocytes; Lung Neoplasms; Metformin; Mice; Mice, Inbred BALB C; Rectal Ne

2022
Metformin suppresses lung adenocarcinoma by downregulating long non-coding RNA (lncRNA) AFAP1-AS1 and secreted phosphoprotein 1 (SPP1) while upregulating miR-3163.
    Bioengineered, 2022, Volume: 13, Issue:5

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cell Line, Tumor; Cell Proliferation; Humans; Lung; Lung Neo

2022
Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib.
    Biomolecules, 2022, 05-28, Volume: 12, Issue:6

    Topics: Adult; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell

2022
Knockdown of NUPR1 Enhances the Sensitivity of Non-small-cell Lung Cancer Cells to Metformin by AKT Inhibition.
    Anticancer research, 2022, Volume: 42, Issue:7

    Topics: Activating Transcription Factor 4; Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus, Type 2; Humans

2022
Tumour, whole-blood, plasma and tissue concentrations of metformin in lung cancer patients.
    British journal of clinical pharmacology, 2023, Volume: 89, Issue:3

    Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lung Neoplasms; Metformin; P

2023
Acute kidney injury and long-term renal effects of alectinib in anaplastic lymphoma kinase-positive non-small cell lung carcinoma: a case report.
    Journal of medical case reports, 2022, Sep-29, Volume: 16, Issue:1

    Topics: Acute Kidney Injury; Aged; Anaplastic Lymphoma Kinase; Anti-Inflammatory Agents; Antineoplastic Agen

2022
Epithelial-mesenchymal transition inhibition by metformin reduces melanoma lung metastasis in a murine model.
    Scientific reports, 2022, 10-22, Volume: 12, Issue:1

    Topics: Animals; Cadherins; Cell Line, Tumor; Cell Movement; Disease Models, Animal; Epithelial-Mesenchymal

2022
Metformin antagonizes nickel-refining fumes-induced cell pyroptosis via Nrf2/GOLPH3 pathway in vitro and in vivo.
    Ecotoxicology and environmental safety, 2022, Dec-01, Volume: 247

    Topics: AMP-Activated Protein Kinases; Animals; Gases; Lung Neoplasms; Male; Metformin; Mice; Mice, Inbred C

2022
The effect of metformin or dipeptidyl peptidase 4 inhibitors on clinical outcomes in metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.
    Thoracic cancer, 2023, Volume: 14, Issue:1

    Topics: Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Dipeptidyl-Peptidase IV Inhibi

2023
Addition of metformin to non-small-cell lung cancer patients with or without diabetes.
    Thoracic cancer, 2023, Volume: 14, Issue:2

    Topics: Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lung Neoplas

2023
Addition of metformin to non-small-cell lung cancer patients with or without diabetes.
    Thoracic cancer, 2023, Volume: 14, Issue:2

    Topics: Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lung Neoplas

2023
Addition of metformin to non-small-cell lung cancer patients with or without diabetes.
    Thoracic cancer, 2023, Volume: 14, Issue:2

    Topics: Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lung Neoplas

2023
Addition of metformin to non-small-cell lung cancer patients with or without diabetes.
    Thoracic cancer, 2023, Volume: 14, Issue:2

    Topics: Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lung Neoplas

2023
Impact of Sotorasib on the Pharmacokinetics and Pharmacodynamics of Metformin, a MATE1/2K Substrate, in Healthy Subjects.
    Clinical pharmacokinetics, 2023, Volume: 62, Issue:2

    Topics: Area Under Curve; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Healthy Volunteers; Humans; Lun

2023
Targeted Delivery of Metformin Against Lung Cancer Cells Via Hyaluronan-Modified Mesoporous Silica Nanoparticles.
    Applied biochemistry and biotechnology, 2023, Volume: 195, Issue:7

    Topics: Diabetes Mellitus, Type 2; Doxorubicin; Drug Delivery Systems; Humans; Hyaluronic Acid; Lung Neoplas

2023
Metabolic and Metabolomic Effects of Metformin in Murine Model of Pulmonary Adenoma Formation.
    Nutrition and cancer, 2023, Volume: 75, Issue:3

    Topics: Adenoma; Animals; Disease Models, Animal; Lung Neoplasms; Metformin; Mice; Weight Gain

2023
Phosphorylation of PHF2 by AMPK releases the repressive H3K9me2 and inhibits cancer metastasis.
    Signal transduction and targeted therapy, 2023, 03-06, Volume: 8, Issue:1

    Topics: AMP-Activated Protein Kinases; Epithelial-Mesenchymal Transition; Homeodomain Proteins; Humans; Lung

2023
A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition.
    International journal of molecular sciences, 2023, Feb-22, Volume: 24, Issue:5

    Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line; Humans; Lung Neoplasms; Metformin; Mutation; P

2023
Metformin regulates expression of DNA methyltransferases through the miR-148/-152 family in non-small lung cancer cells.
    Clinical epigenetics, 2023, 03-23, Volume: 15, Issue:1

    Topics: 3' Untranslated Regions; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; DNA;

2023
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, Jul-14, Volume: 29, Issue:14

    Topics: Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus, Type 2; Disease Progression; Humans; Immune Check

2023
Metformin Resistance Is Associated with Expression of Inflammatory and Invasive Genes in A549 Lung Cancer Cells.
    Genes, 2023, 04-29, Volume: 14, Issue:5

    Topics: A549 Cells; Cell Proliferation; Diabetes Mellitus, Type 2; Humans; Lung Neoplasms; Metformin

2023
Obesity paradox and lung cancer, metformin-based therapeutic opportunity?
    Oncotarget, 2023, 07-01, Volume: 14

    Topics: Body Mass Index; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Metformin; Obesity Paradox

2023
Metformin prevents osteoblast-like potential and calcification in lung cancer A549 cells.
    Journal of biochemical and molecular toxicology, 2023, Volume: 37, Issue:11

    Topics: A549 Cells; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; Epithelial-Mesenchymal Transi

2023
Radiosensitising Effects of Metformin Added to Concomitant Chemoradiotherapy with Cisplatin in Cervical Cancer.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2023, Volume: 35, Issue:11

    Topics: AMP-Activated Protein Kinases; Apoptosis; Cell Line, Tumor; Chemoradiotherapy; Cisplatin; Female; He

2023
Metformin induces ferroptosis through the Nrf2/HO-1 signaling in lung cancer.
    BMC pulmonary medicine, 2023, Sep-25, Volume: 23, Issue:1

    Topics: Cell Line, Tumor; Ferroptosis; Humans; Lung Neoplasms; Metformin; NF-E2-Related Factor 2; Signal Tra

2023
Carbonized polymer dots derived from metformin and L-arginine for tumor cell membrane- and mitochondria-dual targeting therapy.
    Nanoscale, 2023, Nov-16, Volume: 15, Issue:44

    Topics: Apoptosis; Arginine; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Humans; Lung Neoplasms; Me

2023
Metformin plus EGFR TKIs for lung adenocarcinoma.
    The Lancet. Oncology, 2019, Volume: 20, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic;

2019
Knockout model reveals the role of Nischarin in mammary gland development, breast tumorigenesis and response to metformin treatment.
    International journal of cancer, 2020, 05-01, Volume: 146, Issue:9

    Topics: Animals; Antigens, Polyomavirus Transforming; Cell Transformation, Neoplastic; Female; Hypoglycemic

2020
Metformin-sensitized NSCLC cells to osimertinib via AMPK-dependent autophagy inhibition.
    The clinical respiratory journal, 2019, Volume: 13, Issue:12

    Topics: Acrylamides; AMP-Activated Protein Kinases; Aniline Compounds; Autophagy; Carcinoma, Non-Small-Cell

2019
Mendelian randomization study showed no causality between metformin use and lung cancer risk.
    International journal of epidemiology, 2020, 08-01, Volume: 49, Issue:4

    Topics: Causality; Humans; Lung Neoplasms; Mendelian Randomization Analysis; Metformin

2020
Metformin mediated microRNA-7 upregulation inhibits growth, migration, and invasion of non-small cell lung cancer A549 cells.
    Anti-cancer drugs, 2020, Volume: 31, Issue:4

    Topics: Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Gen

2020
Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis.
    Journal of experimental & clinical cancer research : CR, 2020, Jan-06, Volume: 39, Issue:1

    Topics: A549 Cells; Adult; Aged; Aged, 80 and over; Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle Prot

2020
Metformin attenuates adhesion between cancer and endothelial cells in chronic hyperglycemia by recovery of the endothelial glycocalyx barrier.
    Biochimica et biophysica acta. General subjects, 2020, Volume: 1864, Issue:4

    Topics: A549 Cells; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Cell Adhesion; Cells, Cultur

2020
Metformin Mitigates Nickel-Elicited Angiopoietin-Like Protein 4 Expression via HIF-1α for Lung Tumorigenesis.
    International journal of molecular sciences, 2020, Jan-17, Volume: 21, Issue:2

    Topics: Angiopoietin-Like Protein 4; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cell Transformation,

2020
Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1.
    Cell death & disease, 2020, 02-10, Volume: 11, Issue:2

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Carbazoles; Carcinoma, Non-Sma

2020
Metformin and everolimus in neuroendocrine tumours: A synergic effect?
    Clinics and research in hepatology and gastroenterology, 2020, Volume: 44, Issue:6

    Topics: Aged; Antineoplastic Agents; Cohort Studies; Diabetes Mellitus; Digestive System Neoplasms; Drug Syn

2020
A Cohort Study of Exposure to Antihyperglycemic Therapy and Survival in Patients with Lung Cancer.
    International journal of environmental research and public health, 2020, 03-07, Volume: 17, Issue:5

    Topics: Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lung Neoplasms; Male

2020
Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer.
    JAMA oncology, 2020, 05-01, Volume: 6, Issue:5

    Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Metf

2020
Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer-Reply.
    JAMA oncology, 2020, 05-01, Volume: 6, Issue:5

    Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Metf

2020
Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer.
    Anticancer research, 2020, Volume: 40, Issue:4

    Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents, N

2020
Mendelian randomization applied to pharmaceutical use: the case of metformin and lung cancer.
    International journal of epidemiology, 2020, 08-01, Volume: 49, Issue:4

    Topics: Genome-Wide Association Study; Humans; Lung Neoplasms; Mendelian Randomization Analysis; Metformin;

2020
On the use of Mendelian randomization to assess the consequences of metformin exposure.
    International journal of epidemiology, 2020, 08-01, Volume: 49, Issue:4

    Topics: Causality; Genetic Variation; Humans; Lung Neoplasms; Mendelian Randomization Analysis; Metformin

2020
Genetic instrument selection for Mendelian randomization explorations of drug target effects.
    International journal of epidemiology, 2020, 08-01, Volume: 49, Issue:4

    Topics: Causality; Humans; Lung Neoplasms; Mendelian Randomization Analysis; Metformin; Pharmaceutical Prepa

2020
Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer.
    Life sciences, 2020, Sep-01, Volume: 256

    Topics: A549 Cells; AMP-Activated Protein Kinase Kinases; Animals; Antibodies, Monoclonal, Humanized; Antine

2020
Diabetes, Metformin, and Lung Cancer: Retrospective Study of the Korean NHIS-HEALS Database.
    Clinical lung cancer, 2020, Volume: 21, Issue:6

    Topics: Adult; Aged; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypog

2020
Respiratory outcomes of metformin use in patients with type 2 diabetes and chronic obstructive pulmonary disease.
    Scientific reports, 2020, 06-24, Volume: 10, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Hospitalization; Humans; Hypoglyc

2020
Metformin and better survival in type 2 diabetes patients with NSCLC during EGFR-TKI treatment: Implications of miR-146a?
    The clinical respiratory journal, 2020, Volume: 14, Issue:12

    Topics: Diabetes Mellitus, Type 2; ErbB Receptors; Humans; Lung Neoplasms; Metformin; MicroRNAs; Mutation

2020
The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer.
    Scientific reports, 2020, 09-11, Volume: 10, Issue:1

    Topics: Afatinib; Aged; Aged, 80 and over; Antacids; Antineoplastic Combined Chemotherapy Protocols; Asian P

2020
Dual polymeric prodrug co-assembled nanoparticles with precise ratiometric co-delivery of cisplatin and metformin for lung cancer chemoimmunotherapy.
    Biomaterials science, 2020, Oct-21, Volume: 8, Issue:20

    Topics: Animals; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cisplatin; Immunothera

2020
The Associations of Aspirin, Statins, and Metformin With Lung Cancer Risk and Related Mortality: A Time-Dependent Analysis of Population-Based Nationally Representative Data.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021, Volume: 16, Issue:1

    Topics: Aspirin; Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms;

2021
Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC).
    Cancer immunology, immunotherapy : CII, 2021, Volume: 70, Issue:4

    Topics: Antineoplastic Agents, Immunological; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female;

2021
Metformin induced lactic acidosis impaired response of cancer cells towards paclitaxel and doxorubicin: Role of monocarboxylate transporter.
    Biochimica et biophysica acta. Molecular basis of disease, 2021, 03-01, Volume: 1867, Issue:3

    Topics: A549 Cells; Acidosis, Lactic; Animals; Antineoplastic Agents; Breast Neoplasms; Diabetes Mellitus, T

2021
The effect of metformin in EML
    Biochemical pharmacology, 2021, Volume: 183

    Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Sur

2021
Metformin use and lung cancer survival: a population-based study in Norway.
    British journal of cancer, 2021, Volume: 124, Issue:5

    Topics: Adenocarcinoma of Lung; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lu

2021
One Metformin a Day, Keeps Lung Cancer Away! Or Does It?
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021, Volume: 16, Issue:1

    Topics: Aspirin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Lung Neoplasms

2021
Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy.
    Theranostics, 2021, Volume: 11, Issue:4

    Topics: Animals; Apoptosis; B7-H1 Antigen; Breast Neoplasms; Cell Proliferation; Female; Humans; Hypoglycemi

2021
Fer and FerT Govern Mitochondrial Susceptibility to Metformin and Hypoxic Stress in Colon and Lung Carcinoma Cells.
    Cells, 2021, 01-07, Volume: 10, Issue:1

    Topics: Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; Humans; Lung Neoplasms; Metformin; Mitochondria;

2021
Metformin impairs cisplatin resistance effects in A549 lung cancer cells through mTOR signaling and other metabolic pathways.
    International journal of oncology, 2021, Volume: 58, Issue:6

    Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplati

2021
Crocin and Metformin suppress metastatic breast cancer progression via VEGF and MMP9 downregulations: in vitro and in vivo studies.
    Molecular and cellular biochemistry, 2021, Volume: 476, Issue:9

    Topics: Animals; Apoptosis; Breast Neoplasms; Carotenoids; Cell Proliferation; Disease Progression; Drug The

2021
Inhalable Porous Microspheres Loaded with Metformin and Docosahexaenoic Acid Suppress Tumor Metastasis by Modulating Premetastatic Niche.
    Molecular pharmaceutics, 2021, 07-05, Volume: 18, Issue:7

    Topics: Administration, Inhalation; Animals; Apoptosis; Breast Neoplasms; Cell Proliferation; Docosahexaenoi

2021
Inhibition of AKT Enhances the Sensitivity of NSCLC Cells to Metformin.
    Anticancer research, 2021, Volume: 41, Issue:7

    Topics: AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-

2021
The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.
    Oncology, 2021, Volume: 99, Issue:9

    Topics: Carcinoma, Non-Small-Cell Lung; Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agen

2021
Forging a Path for Metformin Use in Inoperable Locally Advanced Non-Small Cell Lung Cancer.
    JAMA oncology, 2021, 09-01, Volume: 7, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; H

2021
Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes.
    Biomolecules, 2021, 08-21, Volume: 11, Issue:8

    Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Diabetes Complications

2021
Metformin use and survival after non-small cell lung cancer: A cohort study in the US Military health system.
    International journal of cancer, 2017, 07-15, Volume: 141, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus, Type 2; Female; H

2017
Metformin Attenuates Radiation-Induced Pulmonary Fibrosis in a Murine Model.
    Radiation research, 2017, Volume: 188, Issue:1

    Topics: Animals; Female; Lung Neoplasms; Metformin; Mice; Pulmonary Fibrosis; Radiation Pneumonitis; Radiati

2017
Metformin and lung cancer risk in patients with type 2 diabetes mellitus.
    Oncotarget, 2017, Jun-20, Volume: 8, Issue:25

    Topics: Adult; Aged; Aged, 80 and over; Comorbidity; Databases, Factual; Diabetes Mellitus, Type 2; Female;

2017
Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways.
    BMC cancer, 2017, 05-02, Volume: 17, Issue:1

    Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Lung Ne

2017
Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors.
    Future oncology (London, England), 2017, Volume: 13, Issue:19

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Gastrointestinal Neoplasms; Huma

2017
Metformin synergistic pemetrexed suppresses non-small-cell lung cancer cell proliferation and invasion in vitro.
    Cancer medicine, 2017, Volume: 6, Issue:8

    Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Prolife

2017
Metformin Has Positive Therapeutic Effects in Colon Cancer and Lung Cancer.
    The American journal of the medical sciences, 2017, Volume: 354, Issue:3

    Topics: Aged; Antineoplastic Agents; Cohort Studies; Colonic Neoplasms; Diabetes Mellitus, Type 2; Disease-F

2017
Statistically controlled identification of differentially expressed genes in one-to-one cell line comparisons of the CMAP database for drug repositioning.
    Journal of translational medicine, 2017, 09-29, Volume: 15, Issue:1

    Topics: Carcinoma, Non-Small-Cell Lung; Cell Line; Databases, Genetic; Drug Repositioning; Gene Expression R

2017
Combination of Solamargine and Metformin Strengthens IGFBP1 Gene Expression Through Inactivation of Stat3 and Reciprocal Interaction Between FOXO3a and SP1.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2017, Volume: 43, Issue:6

    Topics: A549 Cells; Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell

2017
PGC-1alpha levels correlate with survival in patients with stage III NSCLC and may define a new biomarker to metabolism-targeted therapy.
    Scientific reports, 2017, 11-30, Volume: 7, Issue:1

    Topics: Biomarkers; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Gene Expression; Gl

2017
Metformin Sensitizes Non-small Cell Lung Cancer Cells to an Epigallocatechin-3-Gallate (EGCG) Treatment by Suppressing the Nrf2/HO-1 Signaling Pathway.
    International journal of biological sciences, 2017, Volume: 13, Issue:12

    Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Catechin; Cell Line; Cell Line, Tumor; Female; H

2017
Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study.
    PloS one, 2018, Volume: 13, Issue:1

    Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus; Female; Humans; Hypoglyc

2018
Prognostic value of metformin for non-small cell lung cancer patients with diabetes.
    World journal of surgical oncology, 2018, Mar-20, Volume: 16, Issue:1

    Topics: Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diabetes Mellitus, Type 2; Female; F

2018
Metformin and Lung Cancer: The Final Blow to the Obesity Paradox?
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018, Volume: 13, Issue:4

    Topics: Humans; Lung Neoplasms; Metformin; Obesity; Risk Factors

2018
Interpretation of Results from Under-accruing Studies.
    The oncologist, 2018, Volume: 23, Issue:7

    Topics: Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Metformin; Paclita

2018
Effect of metformin in the prognosis of patients with smallcell lung cancer combined with diabetes mellitus.
    Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2018, Volume: 27, Issue:9

    Topics: China; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lung Neopl

2018
Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018, Volume: 13, Issue:11

    Topics: Aged; AMP-Activated Protein Kinase Kinases; Antineoplastic Combined Chemotherapy Protocols; Apoptosi

2018
Metformin synergistically enhances the antitumor activity of the third-generation EGFR-TKI CO-1686 in lung cancer cells through suppressing NF-κB signaling.
    The clinical respiratory journal, 2018, Volume: 12, Issue:12

    Topics: Acrylamides; Apoptosis; Cell Line, Tumor; Cell Proliferation; China; Drug Resistance; Drug Synergism

2018
The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC.
    EBioMedicine, 2018, Volume: 37

    Topics: A549 Cells; Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Carcinoma, Non-Sma

2018
Metformin Inhibited Growth, Invasion and Metastasis of Esophageal Squamous Cell Carcinoma in Vitro and in Vivo.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 51, Issue:3

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation

2018
Impact of metformin use on survival outcomes in non-small cell lung cancer treated with platinum.
    Medicine, 2018, Volume: 97, Issue:51

    Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus, Type 2; Female; Foll

2018
Inflammatory bowel disease associated with the combination treatment of nivolumab and metformin: data from the FDA adverse event reporting system.
    Cancer chemotherapy and pharmacology, 2019, Volume: 83, Issue:3

    Topics: Adverse Drug Reaction Reporting Systems; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Age

2019
Metformin Inhibit Lung Cancer Cell Growth and Invasion in Vitro as Well as Tumor Formation in Vivo Partially by Activating PP2A.
    Medical science monitor : international medical journal of experimental and clinical research, 2019, Jan-29, Volume: 25

    Topics: A549 Cells; Animals; Apoptosis; bcl-2-Associated X Protein; Cell Cycle; Cell Line, Tumor; Cell Proli

2019
Metformin and tenovin-6 synergistically induces apoptosis through LKB1-independent SIRT1 down-regulation in non-small cell lung cancer cells.
    Journal of cellular and molecular medicine, 2019, Volume: 23, Issue:4

    Topics: Acetylation; Adenocarcinoma of Lung; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Ap

2019
Metformin enhances the radiosensitizing effect of cisplatin in non-small cell lung cancer cell lines with different cisplatin sensitivities.
    Scientific reports, 2019, 02-04, Volume: 9, Issue:1

    Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Cisplatin; Gene Expression Regulation, Neoplastic; Human

2019
CHTM1 regulates cancer cell sensitivity to metabolic stress via p38-AIF1 pathway.
    Journal of experimental & clinical cancer research : CR, 2019, Jun-20, Volume: 38, Issue:1

    Topics: A549 Cells; Apoptosis Inducing Factor; Cell Line, Tumor; Cell Survival; Gene Expression Regulation,

2019
Nootkatone, an AMPK activator derived from grapefruit, inhibits KRAS downstream pathway and sensitizes non-small-cell lung cancer A549 cells to adriamycin.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2019, Volume: 63

    Topics: A549 Cells; AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols;

2019
Cancer research at CHEST 2012 conference.
    Journal of the National Cancer Institute, 2013, Mar-06, Volume: 105, Issue:5

    Topics: Biomedical Research; Bronchoalveolar Lavage Fluid; Cancer Care Facilities; Carcinoma, Non-Small-Cell

2013
Comment on: Smiechowski et al. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care 2013;36:124-129.
    Diabetes care, 2013, Volume: 36, Issue:3

    Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lung Neoplasms; Male; Metformin

2013
Response to comment on: Smiechowski et al. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care 2013;36:124-129.
    Diabetes care, 2013, Volume: 36, Issue:3

    Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lung Neoplasms; Male; Metformin

2013
Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
    American journal of respiratory cell and molecular biology, 2013, Volume: 49, Issue:2

    Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents;

2013
[Metformin effect on urethane-induced tumorigenesis in mice].
    Voprosy onkologii, 2012, Volume: 58, Issue:4

    Topics: Adenoma; Administration, Oral; Animals; Anticarcinogenic Agents; Carcinogens; Cell Transformation, N

2012
Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK.
    British journal of cancer, 2013, May-28, Volume: 108, Issue:10

    Topics: Adenylate Kinase; Animals; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Non-Small-Cell Lung; C

2013
Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Jul-01, Volume: 19, Issue:13

    Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Smal

2013
Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling.
    Cancer prevention research (Philadelphia, Pa.), 2013, Volume: 6, Issue:8

    Topics: AMP-Activated Protein Kinases; Animals; Carcinogens; Cell Transformation, Neoplastic; Energy Metabol

2013
K‑ras gene mutation as a predictor of cancer cell responsiveness to metformin.
    Molecular medicine reports, 2013, Volume: 8, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Pr

2013
[Study on the anti-Lewis lung carcinoma effect of metformin combined with MCT1 inhibitor CHC].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2013, Volume: 44, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Lewis Lung; Coumaric

2013
Metformin inhibits lung cancer cells proliferation through repressing microRNA-222.
    Biotechnology letters, 2013, Volume: 35, Issue:12

    Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferati

2013
Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line.
    International journal of oncology, 2013, Volume: 43, Issue:6

    Topics: AC133 Antigen; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antigens, CD; Antineoplastic Combine

2013
Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells.
    Lung cancer (Amsterdam, Netherlands), 2013, Volume: 82, Issue:3

    Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotherapy, Adjuvan

2013
Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, May-15, Volume: 20, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell M

2014
Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, May-15, Volume: 20, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell M

2014
Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, May-15, Volume: 20, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell M

2014
Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, May-15, Volume: 20, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell M

2014
Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, May-15, Volume: 20, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell M

2014
Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, May-15, Volume: 20, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell M

2014
Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, May-15, Volume: 20, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell M

2014
Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, May-15, Volume: 20, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell M

2014
Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, May-15, Volume: 20, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell M

2014
Modulation by metformin of molecular and histopathological alterations in the lung of cigarette smoke-exposed mice.
    Cancer medicine, 2014, Volume: 3, Issue:3

    Topics: Animals; Apoptosis; DNA Adducts; DNA Damage; Humans; Lung Neoplasms; Metformin; Mice; MicroRNAs; Smo

2014
Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis.
    PloS one, 2014, Volume: 9, Issue:4

    Topics: Adenocarcinoma; Blotting, Western; Cell Division; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assa

2014
Repression of phosphoinositide-dependent protein kinase 1 expression by ciglitazone via Egr-1 represents a new approach for inhibition of lung cancer cell growth.
    Molecular cancer, 2014, Jun-13, Volume: 13

    Topics: 3-Phosphoinositide-Dependent Protein Kinases; AMP-Activated Protein Kinases; Apoptosis; Carcinoma, N

2014
Effect of mitochondrial metabolism-interfering agents on cancer cell mitochondrial function and radio/chemosensitivity.
    Anti-cancer drugs, 2014, Volume: 25, Issue:10

    Topics: Amiodarone; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Docetaxel; Drug Resis

2014
Metformin decreases lung cancer risk in diabetic patients in a dose-dependent manner.
    Lung cancer (Amsterdam, Netherlands), 2014, Volume: 86, Issue:2

    Topics: Adolescent; Adult; Aged; Comorbidity; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents

2014
Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status.
    Oncotarget, 2014, Dec-30, Volume: 5, Issue:24

    Topics: AMP-Activated Protein Kinase Kinases; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non

2014
One author replies.
    American journal of epidemiology, 2014, Dec-15, Volume: 180, Issue:12

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lung Neoplasms; Metformin

2014
Re.: "Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis".
    American journal of epidemiology, 2014, Dec-15, Volume: 180, Issue:12

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lung Neoplasms; Metformin

2014
Re: "reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis".
    American journal of epidemiology, 2014, Dec-01, Volume: 180, Issue:11

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lung Neoplasms; Metformin

2014
One author replies.
    American journal of epidemiology, 2014, Dec-01, Volume: 180, Issue:11

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lung Neoplasms; Metformin

2014
Survival of patients with stage IV lung cancer with diabetes treated with metformin.
    American journal of respiratory and critical care medicine, 2015, Feb-15, Volume: 191, Issue:4

    Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Diabetes Mellitu

2015
β-elemene inhibited expression of DNA methyltransferase 1 through activation of ERK1/2 and AMPKα signalling pathways in human lung cancer cells: the role of Sp1.
    Journal of cellular and molecular medicine, 2015, Volume: 19, Issue:3

    Topics: AMP-Activated Protein Kinases; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation;

2015
Metformin: a modulator of bevacizumab activity in cancer? A case report.
    Cancer biology & therapy, 2015, Volume: 16, Issue:2

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Beva

2015
Metformin use and lung cancer risk in patients with diabetes.
    Cancer prevention research (Philadelphia, Pa.), 2015, Volume: 8, Issue:2

    Topics: Adult; Aged; Carcinoma; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agen

2015
Disruption of BASIGIN decreases lactic acid export and sensitizes non-small cell lung cancer to biguanides independently of the LKB1 status.
    Oncotarget, 2015, Mar-30, Volume: 6, Issue:9

    Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Basigin; Biological Transport;

2015
Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis.
    The Biochemical journal, 2015, Jul-15, Volume: 469, Issue:2

    Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents, Non-Steroi

2015
Metformin use improves the survival of diabetic combined small-cell lung cancer patients.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:10

    Topics: Aged; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Lung Neoplasms; Mal

2015
Metformin Use and Lung Cancer Risk--Letter.
    Cancer prevention research (Philadelphia, Pa.), 2015, Volume: 8, Issue:8

    Topics: Carcinoma; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lung Neoplasms; Male; Met

2015
Prognosis of small cell lung cancer patients with diabetes treated with metformin.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015, Volume: 17, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Che

2015
No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK.
    Pharmacoepidemiology and drug safety, 2015, Volume: 24, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Colorectal Neoplasms; Databases, Factual; Diabetes

2015
Combinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung Cancer.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Adult; Aged; Antibodies, Monoclonal; Arrestins; beta-Arrestins; Cell Line, Tumor; Combined Modality

2015
Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
    Cancer letters, 2015, Dec-01, Volume: 369, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small

2015
NLK functions to maintain proliferation and stemness of NSCLC and is a target of metformin.
    Journal of hematology & oncology, 2015, Oct-26, Volume: 8

    Topics: Adult; Aged; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Female;

2015
Lasting glycolytic stress governs susceptibility to urethane-induced lung carcinogenesis in vivo and in vitro.
    Toxicology letters, 2016, Jan-05, Volume: 240, Issue:1

    Topics: Animals; Carcinogenesis; Carcinogens; Cell Line, Tumor; Deoxyglucose; Disease Models, Animal; Diseas

2016
Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.
    Oncotarget, 2016, Jan-26, Volume: 7, Issue:4

    Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apopt

2016
Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30.
    Cancer science, 2016, Volume: 107, Issue:4

    Topics: Acetyltransferases; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene E

2016
Metformin use and survival from lung cancer: A population-based cohort study.
    Lung cancer (Amsterdam, Netherlands), 2016, Volume: 94

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2016
Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation.
    International journal of oncology, 2016, Volume: 48, Issue:5

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; B7-H1 Antigen; Cell Line, Tumor; Cell

2016
Activation of autophagy flux by metformin downregulates cellular FLICE-like inhibitory protein and enhances TRAIL- induced apoptosis.
    Oncotarget, 2016, Apr-26, Volume: 7, Issue:17

    Topics: Adenocarcinoma; Apoptosis; Autophagy; Biomarkers, Tumor; CASP8 and FADD-Like Apoptosis Regulating Pr

2016
Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma.
    Scientific reports, 2016, Apr-15, Volume: 6

    Topics: Cell Line, Tumor; Cisplatin; Fractals; Glycolysis; Humans; Lung Neoplasms; Mesothelioma; Mesotheliom

2016
Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway.
    Oncotarget, 2016, Jun-07, Volume: 7, Issue:23

    Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor;

2016
Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer.
    The Journal of thoracic and cardiovascular surgery, 2016, Volume: 152, Issue:1

    Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease-Free Sur

2016
Pre-existing diabetes and lung cancer prognosis.
    British journal of cancer, 2016, 06-28, Volume: 115, Issue:1

    Topics: Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lung Neoplasms; Metformin; Mid

2016
Role of metformin in lung cancer treatment and prevention: Are we any closer to the answer?
    The Journal of thoracic and cardiovascular surgery, 2016, Volume: 152, Issue:1

    Topics: Humans; Hypoglycemic Agents; Lung Neoplasms; Metformin

2016
Metformin for chemo-radio-sensitization of NSCLC.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016, Volume: 120, Issue:2

    Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Metformin

2016
Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC.
    Scientific reports, 2016, 08-04, Volume: 6

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; beta-Arrestins; Carcinoma, Non-Small-Cell Lung; Cell

2016
Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer.
    BMC cancer, 2016, 08-12, Volume: 16

    Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic

2016
Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study.
    Lung cancer (Amsterdam, Netherlands), 2016, Volume: 99

    Topics: Aged; Aged, 80 and over; Cause of Death; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans;

2016
Impact of H3K27 Demethylase Inhibitor GSKJ4 on NSCLC Cells Alone and in Combination with Metformin.
    Anticancer research, 2016, Volume: 36, Issue:11

    Topics: Benzazepines; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Enzyme Inhibitors; Humans; Lung Neop

2016
Combination of 2-deoxy d-glucose and metformin for synergistic inhibition of non-small cell lung cancer: A reactive oxygen species and P-p38 mediated mechanism.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2016, Volume: 84

    Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Carcinoma, Non-

2016
Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer.
    Journal of controlled release : official journal of the Controlled Release Society, 2016, 12-28, Volume: 244, Issue:Pt A

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung;

2016
Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention.
    Cancer prevention research (Philadelphia, Pa.), 2017, Volume: 10, Issue:2

    Topics: Adenoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Chemoprevention; Dose-Response Rel

2017
Dual Functional LipoMET Mediates Envelope-type Nanoparticles to Combinational Oncogene Silencing and Tumor Growth Inhibition.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2017, 07-05, Volume: 25, Issue:7

    Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cholesterol; Endosomes; Female; Gene Expr

2017
Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer.
    The Annals of pharmacotherapy, 2009, Volume: 43, Issue:3

    Topics: Acidosis, Lactic; Adenocarcinoma; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injur

2009
Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy.
    Breast cancer research and treatment, 2010, Volume: 123, Issue:2

    Topics: Adipokines; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Autophagy; Biomarkers; Bl

2010
Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells.
    International journal of radiation oncology, biology, physics, 2010, Sep-01, Volume: 78, Issue:1

    Topics: AMP-Activated Protein Kinases; Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms; Cell Cycle

2010
Chemoprevention meets glucose control.
    Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:9

    Topics: Animals; Blood Glucose; Carcinoma; Chemoprevention; Humans; Hypoglycemic Agents; Lung Neoplasms; Med

2010
Metformin prevents tobacco carcinogen--induced lung tumorigenesis.
    Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:9

    Topics: Adenylate Kinase; Administration, Oral; Animals; Antineoplastic Agents; Carcinogens; Carcinoma; Drug

2010
AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor.
    Neuro-oncology, 2011, Volume: 13, Issue:2

    Topics: Active Transport, Cell Nucleus; Adenocarcinoma; AMP-Activated Protein Kinase Kinases; AMP-Activated

2011
Teaching an old drug new tricks: metformin as a targeted therapy for lung cancer.
    Seminars in thoracic and cardiovascular surgery, 2010,Autumn, Volume: 22, Issue:3

    Topics: Antineoplastic Agents; Humans; Hypoglycemic Agents; Lung Neoplasms; Metformin; Sirolimus; Smoking; T

2010
Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types.
    Cancer research, 2011, May-01, Volume: 71, Issue:9

    Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Car

2011
Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes.
    Cancer, 2011, Nov-15, Volume: 117, Issue:22

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L

2011
Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo.
    Neoplasia (New York, N.Y.), 2011, Volume: 13, Issue:5

    Topics: AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Proliferatio

2011
Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153.
    Neoplasma, 2011, Volume: 58, Issue:6

    Topics: Adenocarcinoma; Animals; Apoptosis; Blotting, Western; Cell Proliferation; Humans; Hypoglycemic Agen

2011
Caveolin-1 is essential for metformin inhibitory effect on IGF1 action in non-small-cell lung cancer cells.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2012, Volume: 26, Issue:2

    Topics: Base Sequence; Carcinoma, Non-Small-Cell Lung; Caveolin 1; Cell Line, Tumor; Forkhead Box Protein O3

2012
Antiproliferative action of metformin in human lung cancer cell lines.
    Oncology reports, 2012, Volume: 28, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; BALB 3T3 Cells; Caspases

2012
The use of metformin and the incidence of lung cancer in patients with type 2 diabetes.
    Diabetes care, 2013, Volume: 36, Issue:1

    Topics: Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycem

2013
Metformin does not alter the risk of lung cancer: a case-control analysis.
    Lung cancer (Amsterdam, Netherlands), 2012, Volume: 78, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus; Female; Humans; Hypoglycemi

2012
The effect of metformin and thiazolidinedione use on lung cancer in diabetics.
    BMC cancer, 2012, Sep-14, Volume: 12

    Topics: Case-Control Studies; Diabetes Mellitus; Drug Therapy, Combination; Female; Humans; Hypoglycemic Age

2012
Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.
    Biochemical pharmacology, 2013, Feb-15, Volume: 85, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; DNA Repair;

2013
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:9

    Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Enzyme In

2005
Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth.
    Endocrine-related cancer, 2008, Volume: 15, Issue:3

    Topics: Algorithms; Animals; Carcinoma, Lewis Lung; Cell Proliferation; Diet, Atherogenic; Drug Evaluation,

2008
Pharmacological enhancement and short-term stimulation of blood fibrinolytic activity.
    Scandinavian journal of haematology, 1969, Volume: 6, Issue:6

    Topics: Adolescent; Adult; Aged; Aminocaproates; Anticholesteremic Agents; Arteriosclerosis; Arthritis, Rheu

1969